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here ;
ab antibody
ACTH Adrenocorticotropic hormone
ag antigen
CCK Cholecystokinin
CCIC-V Cholecystokinin varient
CHR units Crick, Harper Raper units
CU Clinical Unit (of secretin)
Gl-tract Gastrointestinal tract
G.I.H, Gastrointestinal Hormone (Research Institute, Karolinska)
G.I.P. Gastric Inhibitory Peptide
5-HT 5-hydroxytryptamine
(m)IDU (milli) Ivy Dog Unit
KIU Kallikrein Inactivator Unit
P.V.P . Polyvinylpyrrolidone
PZ Pancreozymin
V.I.P. Vasoactive In.testinal Peptide
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Summary
This thesis describes in full the development of a 
biological method of estimating cholecystokinin (CCK) in human 
serum by superfusion of rabbit gall-bladder strips, from the 
early stages of the manual technique, which would estimate 
approximately twelve samples per day, to the more sophisticated 
and clinically useful automated technique of today which can 
estimate up to forty eight sample solutions in duplicate 
each day.
In developing this bioassay for CCK it was necessary 
to determine whether the gall-bladder preparation was stable 
for the duration of the experiment, and also whether or not 
there were other factors influencing the response of the gall­
bladder strips to a given stimulus. It was also necessary to 
determine whether the assay was entirely specific for CCK in 
human serum and to counteract any possible degradation of CCK 
during processing and storage of serum.
In the light of the findings during the above experiments 
the technique was modified to eliminate errors that would other­
wise be made in estimating the CCK content of a serum sample.
Since our attempts to set up a radioimmunoassay were 
unsuccessful a comparison of this bioassay was made with
another groups’ radioimmunoassay. Although no direct comparison 
could be made as the two assays measure CCK in totally 
different units, nevertheless a straight line relationship 
between the two very different methods was found, and this 
experiment led directly to the discovery by bioassay of CCK 
mimicking substances in serum.
The action of trypsin on CCK has been clearly 
demonstrated and its ability to release the C-terminal octa 
and more probably the dodeca peptide, both of which are 
considerably more active than the full molecule, is beyond 
question.
It is therefore important that an enzyme inhibitor is 
added to blood samples to prevent this spontaneous brealcdown of 
more active fragments and prevent false readings of serum 
cholecystokinin activity.
During chromatographic investigations a new molecule in 
human serum which possessed cholecystokinetic activity but had 
a molecular weight in excess of 30,000 (c/f 3,900 for normal 
CCK) was discovered. This molecule appeared to predominate in 
the fasting state but to decrease in concentration during the 
response to a meal.
The practical use of measuring serum CCK is demonstrated 
in some clinical trials in which CCK’s target organs are removed 
or the stimulation for its release is modified by various 
surgical procedures. Some interesting changes are noted.
-1-
INTRODUCTION
Cholecystokinin (CCK) is a 33 araino acid peptide hormone found
in thé upper part of the gastro-inteatinal tract (GI tièact). Classified
with the kinins by virtue of its action on smooth muscle, it
is released from the duodenum on stimulus with fat or acid
and is now known to have at least two main functions;
1. It Causes the gall-bladder to contract thereby mixing 
the duodenal contents with bile, emulsifying the fat and 
facilitating digestion,
2, It stimulates the release of enzymes from the pancreas.
In addition there is evidence that it exerts some control over 
the pyloric sphincter and has some effect on gut motility.
The physiology and biochemistry of CCK are not well understood.
This appears to be due to;
a) difficulties in estimating the concentration of CCK, 
and,
b) the lack of coiumercial source of CCK of sufficient 
purity and guaranteed activity to allow research work to proceed 
without constant doubts about the reliability of the results*
This project set out to;
1. Establish at least one readily acceptable form of routine 
assay for CCK.
2, To compare the results obtained by bioassay with those obtained 
simultaneously by radioimmunoassay - if possible,
3, To use the assays to study the changes in blood concentrations 
of CCK following meals after different gastric surgery procedures, 
and note any changes related to pathological conditions, é,g.
4, Tp determine the active form or forms in which CCK normally 
exists in blood serum,
5, Tp study the relative potencies Of the commercial preparations 
of CCK available and assess their values as standards.
SECTION A
- 3 "
HISTORICAL REVIEW
Chapter Al
ÀX.1 The Very Beginning
It is difficult to assess the exact moiaent when interest in 
the function éf the pancreas and the origin and function of bile 
began to pave the way for the discovery of the numerous peptide 
hormones of the upper gastro-intestinal ttnct known today, ,
The pancreatic duct was finit discovered in the turkey by 
Merits Hoffman in 1641. One year later the existence of a duct 
system in the human pancreas mas published by Wirsung to whom 
Hoffman had coiaauhicated his findings in the turkey (Wirsung, 1642), 
Then began the argument as to whether the function of the duct was 
secretory or excretory. In 1671 Regnieir de Craaf published the 
first report of the collection by cannulation of pancreatic juice, : 
Interest in the p m  ere as was mainly centred on the role it 
played in digestion, and little seems to have been learnt through 
the 18th and early 19th centuries. In 1826 Tiedemann and Gmelin 
quoted both Haller and Hagendie as saying effectively that despite 
numerous hypotheses nothing was really known about the function of 
this enigmatic gland, '
However, it was in 1825, in work that has been largely ignored 
outside France, that the first hint that hormones - a term then
-4-
mdcnowu - could be iuvolved in digestion was found by the two 
Frenchmen LeureC and Lassaigne (1825). This was published in 
their book which was entered for the same competition as that 
of Xiedmami and Gmelin» Leuret and Lassaigne (1825) found 
that the introduction of vinegar into the duodenum stimulated 
bile flow and secretion of pancreatic juice together with 
a dilation of the orifices of the pancreatic and bile ducts in 
the duodenum. They also noted that the contents of the stomach 
being acid, their observation was clearly important in the 
understanding of digestion, since the movement of the acid 
contents of the stomach into the duodenum could.be expected 
to have a similar effect.
The next major observation was by.Bernstein in 1869 who 
showed that pancreatic secretion was not inhibited if all the 
nerves to the pancreas were cut; this led to the postulation 
by Bayliss and Starling in 1902, of a ’chemical reflux’ - a 
change in the function of one organ consequent on maiiipulatioit 
ox a remote structure without the involvement of any nervous 
pathway.
A1.2 The First Gastrointestinal Hormones
. Bayliss and Starling’s postulation (Bayliss and Starling 
1902, 1902a) was based on an experiment with the denervated
— 5 “
jejunum as the chemical source and the éxpcrlnè pancreas as the 
target organ. They noted that a stimulus of 0,4% hydrochloric t
acid in the duodenum produced a flow of pancreatic juice* Tliey 
were then surprised to see the same response to the same stimulus |
in an isolated denervated loop of jejunum. Starling then scraped
some mucosa from the duOdenum, shook it with 0.4% hydrochloric A
acid, filtered, and injected the filtrate into the jugular vein i»
of the dog used in the experiement. Ari immediate response in the li
form of pancreatic output was noted> thus chemical transmitters 
became an established fact. Bayliss and Starling gave the name 
of Secretin to the particular chemical transmitter they assumed 
to have been released at this tin». The term ’hormone* (from 
Greek meaning ’I arouse to activity’ or ’ I excite*) was first 
used by Starling in the fourth of a series of lectures on the 
*Chemical Correlations of the Functions of the Body’ (Starling, 1905).
This was the spark that started the fire of interest in the 
upper gastro-intestinal hormones, the study of nervous reflexes 
being temporarily forgotten, ^
This research led eventually to the discovery of Insulin by 
Banting and Best in 1922 and to the real beginning of the 
Ch olecystokinin story in 1928 with the demonstration of
:,3|
gall-bladder contraction following the injection of a purified 
extract of intestinal mucosa.
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À2i l The Biscovefy and Naming of Chdlecystokinln and Paneredsymlh '
7"-: Contraction'of;.the \güine4Jpig 'gall-bladder 'following ;'an, ' - '%
•injection"of ;â':'purifie4; extfâct .of ■intestinal/.mucoaa 'was; :first ■ : y ' 
demonstrated by Ivy and Oldberg in 1928, the active substance 
was not histamine or choline aiid was hoi thought to be s.ecfetin*
Ivy and Oldberg proposed the name ’Cholecystokinin* ^ classifying 
the unknown homone with thé kinins by virtue of Its action on 
the smooth muscle of the gail-bladdéri no action on blood vessels 
or nociceptive ; nerve endings being;, demonstrated# y  j,. '
Over the next decade several methods for thé preparation of / 
cholecystokinin (CCK):.were:;repôrtéd';'(é,g, ' ' Ivy, Rloster, Lueth and 
Drewyer, 1929; Gunnar, 1939): and the presence of cholecystokinin, 
in the human and rabbit intestine was also demonstrated (Drewyer 
and Ivy, 1930v^^'r^ \\ ^ "
Early expérîmefii!?5' (Lueth, Ivy and Kloster, 1929) showed that 
while injection of a preparation: of cholecystokinin caused contraction 
of the gall-bladder, it was without effect On liver volume or gastric 
motility, although variable action on intes tinal mo tilitÿ was noted.
The reduced response of the diaeased gall-bladder, was also demonstrated 
at this tiioe (Ivy, Drewyer and Orndoff, 1930), and on comparison 
with pituitrin and pilocarpine cholecystokinin was ; found to be
- 7 -
the only substance causing gall-bladder contraction without altering 
blood- pressure or causing a general parasympathetic stimulation 
(Voegtlin and Ivy, 1934).
A new hormone came on the scene in 1943 when Harper and Raper 
showed that the injection of intestinal mucosa extracts increased 
the output of pancreatic amylase and trypsinogen but not the total 
volume of the pancreatic output. Its action was not affected by 
severing the splanchnic or vagus nerves, nor by atropine; it was 
stable in acid solution and at 100°C, but was destroyed by alkali.
This discovery was confirmed by Greengard, Grossman, Woolley and 
Ivy (1944), and the name pancreozymin originally conferred on 
th is hormone by Harper and Raper (1943) was accepted,
A.2.2 Purification of Cholecystokinin and Pancreozymin
The initial stages for the preparation of cholecystokinin 
have-hardly changed in the fifty years of the hormone's history.
Harper and Raper (1943) began their preparation of pancreozymin (PZ) 
by following the procedure of Mellanby (1932) for the preparation 
of secretin. The first metre of pig intestine was extracted with 
alcohol, calcium chloride was added to the extract which was then 
filtered and concentrated. Bile salt (tauroglycocholate)(in dilute 
acetic acid) was added to the concentrate. The precipitate contained 
secretin and was collected by centrifugation, then purified by 
extraction with alcohol and reprecipitation with acetone.
■ rS
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Pancreozymin v/as not adsorbed by the bile acid and remained 
in solution. The supernatant was maturated with sodium chloride 
and left to stand for 2 - 3 days in the dark. A sticky precipitate 
containing pancreozymin formed; this was collected, dissolved in 
water and dried in a desiccator. Variations in the properties of 
commercial bile salts resulted in low yields, ho'wever, and the 
technique was later modified (Crick, Harper and Raper, 1949), 
the secretin being adsorbed on to a bile-charcoal complex. Tliis -
bile-charcoal complex was prepared by adding Nor1te charcoal to
bile, mixing and evaporating to dryness. Tlie solid material was 
extracted with methylated spirit on a boiling water bath, the vSj
suspension filtered and ether added to the filtrate. , A white 
precipitate was allowed to spparate at O^C, The supernatant 
was removed and the precipitate washed with ether and firled*
Yield; 2,14g bile salts/lOOml bile. It was also found necessary 
to mix pig and ox bile to obtain the best adsorption of secretin.
Perhaps it was because of the difficulties in preparation 
that cholecystokinin and pancreozymin were virtually ignored 
through the 1950’s until Professors Jorpes and Hiitt turned their 
attention from secretin in the latter part of the decade. In 
1959 Jorpes and Mutt (1959) while reviewing the current clinical 
aspects of secretin, cholecystokinin and pancreoiçràin, outlined 
their procedure for the preparation of cholecystokinin. ,
-.1
. Again Starting with the first metre of hog intestine, they .
extracted this material with acetic acid for one hour at , 100 C, 
this gave a less balky crude material than; hydrochloric acid. .
The hormones were then adsorbed on to ion exchangers of lion- 
crosslinked polymers, of which alginic acid (polymannùronic vVi
acid) was found to be the best. The hormones were eluted from 
the ion exchanger with hydrochloric acid and precipitated with 
sodium chloride.
Later using the commercial product ’Checkin’ (Vitrum Co.,) 
as their starting material Dhariwal, Schally, Zlayer. Sun, Jorpes 
and Mutt (1964) obtained a 30 fold purification of both : - "j
cholecystokinin and pancreozymin activity in just two steps on
DEAE and CM cellulose columns. In a continuation of these :,Vh
experiments and finding that cholecystokinin and pancreozymin
activities increased proportionally through all purification r V
. ■ ■ . ■ ' - stages using both acidic and basic ion exchangers Jorpes and Mutt ■ .,7
(1966 1)suggested that thO two very different types of activity f /:
were in fact due to the same substance. This work resulted in
cholecystokinin preparations with an activity of 3000 Ivy Dog .
Units per fdlligrmii (IDU/mg), although one preparation had an
activity of 6000 IDU/mg, (An Ivy Dog Unit of cholecystokinin
is that amount of dry material which when dissolved in isotonic
— 10 —
saline solution and injected intravenously to a dog over 10 - 15s ' ♦ 
causes a 1cm rise in the bile pressure within 1 - 5  minutes (Ivy
and Jan^cek, 1959). Bile pressure is measured by the height of
bile maintained in a cannula inserted into the fundus of the
gall-bladder.)
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Chapter A3
Â3.1 Characteristics of Cholecys tokinin
Xu the early days of secretin preparation Bayliss ahd Starling 
(1902) showed that the active substance was non-volatile, thermostabla, 
soluble in aqueous ethanol even at high ethanol concentrations, but 
was insoluble.in absolute ethanol and in ether, it was dialyzablo 
and easily destroyed by proteolytic enzymes, the salts of mercury, 
lead and iron and by oxidation with dilute solutions of potassium 
permanganate. These properties were strong indications of a 
peptide compound.
Professors Jorpes and Hutt. with Dr Jelling began work bn 
secretin in 1949 in response to a request for a clinical preparation 
(Mutt, 1959). They quickly established that, despite claims to 
the contrary, secretin had not at that time been prepared in pure 
form. By the end of the 1950*s Jorpes and Mutt (1959) were 
routinely preparing secretin in pure £orf% : and while; continuing 
studies on the amino acid sequence of secretin, began to turn their 
attention to the related hOrraoues Cholecystokinin and Pancreozyjain, 
Isolation of cholecystokinin and paucreozymin began with the 
preparation of h crude concentrate; the upper intestines, of hogs 
were iromersed in boiling water to. inactivate the, proteolytic enzymes, 
after a few minutes these were minced and extracted with 0.5M acetic
-:v ■
7"
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acid. The active material was .adsorbed onto alginic acid, eluted 
with 0.2M hydrochloric acid and precipitated by saturation with
sodium chloride'. This precipitate contained secretin^ cholecystokinin ■ ■■;;
and pancreozymin* ■ (Jorpes and Mutt, 1959). ' . 'ht
.The precipitate was dissolved in water and fractionated with: 
ethanol, the fraction with the highest secretin activity being ' 
recovered in aqueous solution and precipitated at pH4,5 with sodium ' 
chloride. At this point there was.no marked separation of secretin .7^
from pancreozymin and cholecystokinin. however in the next step 
when the precipitated material was extracted \7ith methanol it was 
found that the bulk of the secretin was mcthanol-spluble, whereas 
the bulk of cholecystokinin and pancreozymin was in the methanol- . . k
insoluble fraction.
Attempts to purify further pancreozyrain from cholecystokinin 
resulted in the observation that every fractionation leading to an 
increase in pancreozymin activity also resulted in a parallel increase, 
in cholecystokinin activity. With these results before them Jorpes 
and Hutt (1966) proposed that cholecystokinin and pancreozymin might 
be two different effects of the same hormone. , .
Five final purification stops (Jorpes, Mutt and Toczko, 1964) 
at last produced an apparently homogeneous polypeptide with both 
cholecystokinin and pancreozymin activities. Then began the 
painstaking work of elucidating the amino acid sequence.
13 " ' . ' ' ' - ' ' : - .
It was first observed that cholecystokinin (baying been discovered 
first It was deemed reasonable to call this polypeptide cholecystokinin 
and denote it as haying a pancreozymin effect) did not contain 
threonine dr cystine/cysteine but did contain methionine. Cleavage 
at the' raethlonyl residues resulted in several fragments, one of ' 
which was identified as aspartylphenylalanine amide (Mutt and Jorpes, 
1967).,' suggesting à C-terminàl sequence identical to gastrin.
Following a final purification step (chromatography at pH8 bn CMC 
(Garboxy Methyl Cellulose)) the elucidation of the amino acid 
sequence was perfectly straightfon-irard, ;
Cleavage with thrombin and trypsin (Mutt and Jorpes, 1968) tfhose 
specificities are known produced five.tryptic peptides* _ Tho amino 
acid sequence of these peptides was determined and the final full 
amino acid sequence of cholecystokinin (Mutt and Jorpes, 1970) was 
shoT'Tu to be:. . - ,
Lys-Ala-Prp-Ser-Gly-Arg— -Val—Ser-Mct-Xle-Lys— "•Asn-Leu-Glu- 
i Scr-Leu-Asp-Pro-Ser-His*^ ...
Arg— Ile-Ser~Asp-Arg— — Agp-Tyr(S0^)-*Met-Gly-Trp-Hot*"Asp-Phe-NH2 
Thé cholecystokinin C-terminal octapeptide amide was synthesised 
almost immediately and shoim to have a considerably greater activity 
on a molar basis, than the whole molecule (Ondetti, Rubin, Engel^
Pluscec and Sheehan, 1970), and in the same paper it was shoim that 
the C-terminal portion of the molecule was the active part, and that
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at least seven amino acids, including the sulphated tyrosine, were 
necessary for biological action. The amide grouping at the 
C-terminus is also essential for gastrin activity (Morley, Tracy 
and Gregory, 1965) and, since no synthetic fragment has been 
synthesised without it (Ondetti et al, 1970) although no specific 
reference can be found, it would seem certain that this amide 
grouping is essential for cholecystokinetic activity. We, (in 
this work) and others (Ondetti et al, 1970) have observed that 
the octapeptide without the sulphate on the tyrosine is inactive 
and may exert an inhibitory effect on the natural molecule.
More recently Mutt (1976) has isolated a form of cholecystokinin 
having 39 amino acids, it is identical to the 33 amino acid form but 
has an additional six amino acids at the N-terminal end in the form 
of the peptide Tyr-Ile-Gln-Gln-Ala-Arg; the activity also appears 
to be equivalent to the 33 amino acid form.
A3.2 Assay of Cholecystokinin
From Ivy’s original in vivo experiments with dogs (Ivy and 
Oldberg, 1928) to the automated superfusion techniques of today 
(Marshall, 1976; Marshall, Egberts and Johnson, 1978) the majority 
of assays for cholecystokinin have been biologically based. X'Jhile 
other peptide hormones have yielded readily to radioimmunoassays, 
such assays for cholecystokinin have been rare, and all have given 
conflicting results (Reeder, Becker, Smith, Rayford and Thompson,
1973; Go, Ryan and Summerskill, 1971; Young, Lazarus and Chis holm,
1969; Harvey, Dowsett, Hartog and Read, 1974; Schlegel and Raptis, 1976)
— 15 —
With only occasional excursions into other species, such as the 
frog (Seager, 1939, 1941), cat (Ivy and Janecek, 1959), and rat (Lin 
and Alphin, 1962) all bioassays until 1969 for cholecystokinin 
appear to have been carried out on anaethetised dogs; cholecystokinin 
activity being measured by the increase in intragall-bladder pressure, 
and pancreozymin by the increased output of amylase in the pancreatic 
juice.
In the late 1960's advances in electronics and the increased 
use of organ baths brought the first in vitro assay for cholecystokinin 
(Amer and Becvar, 1969), where strips of rabbit gall-bladder were 
attached to isometric transducers, although the sensitivity was low - 
only 0.05 IDU (50m IDU) could be detected.
Two years later came the first use of superfusion over isolated 
rabbit gall-bladder using whole blood from an anaethetised cat 
(Berry and Flower, 1971).
.. This technique was then applied to human serum and the first 
sensitive bioassay for cholecystokinin in human serum (Johnson and 
McDermott, 1973) soon followed; this used isolated rabbit gall-bladder 
strips superfused with Krebs balanced salts solution. It is 
essentially this technique, its extensive modification (Marshall, 1976; 
Marshall, Egberts and Johnson, 1978) and the results obtained using 
this technique that form the basis of this thesis together with 
reports of the problems involved in developing a radioimmunoassay.
It would be more correct to say’biological method of estimating’ 
but the word ’bioassay’ is used through this thesis for convenience.
' A4»1.3 Stimulatory Effécta •
Cholecystokiu has beeu shewn to stimulate: intestinal laotility
(liednèr* Ferssoh and Rorsman, 1967) contraction of the/quiet - i.e. 
non-contracting stomach - (Ga^ron, Phillips and
'w.:
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Chapter A4
' A4 .1 Kno^n Functions » Uses and Potential Uses of Cholecystokinin 
(Pancreozymin) /
A4 «1.1 Introduction
From the original experiments o£ Ivy and Oldberg (1928) the 
first function assigned to cholecystokinin was the contraction of 
the gall-bladder* Some fifteen years later stimulation of enzyme 
secretion by the pancreas (Harper and Raper# 1943) was discovered, 
but attributed to another hormone# pattcrebsymin# until the two 
were shown to be identical (Jorpes and Mutt# 1966). Since ;
stimulation of gall-bladder contraction was discovered first the , '
hormone is now generally known as cholecystokinin. ! -- J.
In addition to thèse two main physiological functions# : '
cholecystokinin has also been, shown ui\der experimental conditions# .• !
mainly on animal modeIs# to have a number of effects oii other 
body organs. '
: A4é1.2 Release Mechanisms
Cholecystokinin has been shown to elicit bicarbonate (Rayford,
. Miller aiid Thompson# 1976) and insulin (Unger# Ketterer# Dupre . Ï.
and Eisentrout# 1967) release from the pancreas. It has however 
since bèen shown that insulin was not reieased by CCK but by 
impurities in the CCK preparation used in that study (Hedner, Persson 
and Ursing# 1975).
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Summerskill, 1967), the pyloric sphincter (Grossman, 1973), the
flow of hepatic bile (Jones and Grossman, 1970), the secretion
* > of Brunner’s glands (Stenning and Grossman, 1969), blood flow in the
superior mesenteric artery (Bowen, Pawlik, Fang and Jacobson, 1974),
and pancreatic growth (Barrowman and Mayston, 1974),
A4.1.4 Inhibitory effects
Cholecystokinin has been shown to inhibit; contraction of
the lower oesophageal sphincter (Grossman, 1973); contraction of
the sphincter of Oddi (Ondetti et al, 1970); absorption of fluid,
sodium, potassium and chloride from the jejunum and ileum (Johnson,
1974); motility of the active stomach (Cameron, Phillips and
Summerskill, 1967),
A4.1.5 Action on arterial pressure
Cholecystokinin has been shown to decrease the pressure in
the systemic artery (Post and Hanson, 1975).
A4.1.6 Proven Physiological Effects in Man
To date very few of the effects of cholecystokinin shown in
animals have been demonstrated to hold true for human tissue. It
is however beyond doubt that cholecystokinin causes gall-bladder
contraction (Goldstein, Grant and Margulies, 1974), pancreatic
enzyme secretion (Hanscom, Jacobson and Littman, 1967) and has
some effect on gastric acid secretion or can act as a competitive
inh ibitor of gastrin (Grossman, 1970). More recently (Hedner and
Rorsman, 1972) cholecystokinin has been shown to affect human gut
motility and to decrease small gut transit times.
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A4.1.7 More recent developments
It has been suggested that cholecystokinin may also be a 
satiety signal, and, by negative feedback, instruct the animal 
to stop feeding. After an overnight fast, rats with chronic 
gastric fistulae will continuously sham feed a liquid meal for
several hours (Young^ GibW, Antim, Holt and Smith, 1974), a
quantity of the liquid meal introduced directly into the small 
intestine quickly stops sham feeding and initiates the behavioural 
sequence associated with satiety.
Of several gut hormones injected into the peritoneal cavity 
only cholecystokinin and the C-terminal octapeptide of cholecystokinin 
inhibited sham feeding (Lorenz, Gibbs and Smith, 1978) although the 
dosage given (5-160 IDU/Kg of CCK, or 20-640 IDU/Kg of the octapeptide) 
would appear to be well outside the normal circulating level of this 
hormone. Although cholecystokinin has not yet been shown to 
inhibit feeding in man (Goetz and Sturdevent, 1975) the possibility 
that some forms of obesity are due to a hormone deficiency or a 
failure of the receptor sites on the brain stem must be investigated. 
A4.1.8 Recent use in clinical practice
It has also been shown (Hedner and Rorsham, 1972; Levant,
Kun, Jachna, Sturdevant and Isenberg, 1974) that cholecystokinin 
and its C-terminal octapeptide are both powerful stimulants of 
small bowel motility. Thus patients with prolonged intestinal ileus
màybé relieved by treatment with.cholecystokinin, but this still 
needs evaluation, Cholecystokinin has/also been used as the 
: '."Stimulant for cholecystogrhm investightipns (Goldstein,^  Grant ■ '
/ and Margulies, ,1974) : and pancreatic function tests-, (ïiauscom,■
Jacqbson. and Littmah# 1907), ' ..v =■/:■/•.'•■.■;■.. -.% /\ . : ' ' ; " ^ /''
■ 'A4’*2 Release of.''Cholecystokinin /:
Cholecystokinin is released into the blood gtrèam in respbné# -
, to the {présence ôisfood in tÜe duodénum and jejunum, ' Thé. amount of/,
.... hormone released is related to the rate/at which'food enters the,. -/'' 
upper intestine and thé length of intèstinél imcoma that is 
sti ulated (Johnson, 1974). /.. ..'■/■ r-i‘ " '
■ .. ..,/-''Bie‘ of £xcieuc|f, with which .-'.cholecys tokinin ,if> released/varies '/
■..considerably .with the^ stimulus':giyèhî sosie. foods and digestive/ '•
' products are very effective# others release 'virtually' nb, -'eholehystokihin)
, at all,/ In the first-- group are ; t-aininp acids, fatty.,- acids .greater ' /
', : than nine carbons in,length- and hydrochloric acid, (Meyer ^ 1 9 7 4 ) .  -, ;
In particular the amino acids phenylalanine, : valine- and-methionine'- / .
/were very active and tryptophane rather less active (Go, lhif.fman' and.'/■';■-/ 
/■■-Sma«prskill,-/197,0) /while acid is only a weak relçaser, o'f-phbIccystokinin 
./(Meyer aid/Grossman# 197:1) however, Berry and Flower (19.71); found - 
. hydrochloric acid to be the strongest stimulant for cholecystokinin
/ - release' in the cat, ' although if • therc; was ho /response at O.OllN ’ ;
. thé acid had to be 0,025 - O.llN to evoke this response, : In
contract hydrolytic products of carbohydratea; and glycerol have;
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either ho effect or are weak releasers of cholecystokinin (Go, 1978)* 
Perfusion of the duodenum with a 6 - 12mM calcium solution stimulated 
pancreatic enzyme output and gall-bladder contraction in a manner - 
comparable with exogenous cholecystokinin (Holtemuller, Malagelada, 
McCall and Go, 1976).
A4*3 Location of Choiecystokinin
From the beginning (Ivy and Oldberg, 1928) it has been kno^m 
that cholecystokinin originates in the mucoaa of the upper intestine, 
but it la only in the last decade., with the advent of immunocyto- 
chemical techniques, that the cell respons'i4,le for releasing, and 
probably manufacturing, cholecystokinin has been identified.
Following the work of Pearse (1966, 1966a) a number of , 
peptide hormone-producing cells were grouped together on the basis 
of their cytochemical characteristics. In 1968 Pearse produced 
a much larger series of cells with similar cytochemical properties: 
from the pancreas, pituitary, thyroid, intestine and stomach, cells 
were found which had (I) high oC- glycerophasphate menadione 
reductase, (II) high non-specific esterase and/or cholinostorase, 
(III) fluorogenic amine content (presumed 5HîT), (a) primary,
(b) secondary, (IV) amine precursor uptake, (V) amino, acid 
decarboxylase (presumed).
Since no single, term could be found to cover prbpartie.s III»
IV and V above, the letters APUD were used to indicate Amine content
: ' . - 20 "/V . ' . \ \ \
and Amine and Precursor Uptake and Decarboxylation. Cells containing 
the three characteristics together with one or other of the associated
enzyme systems have since been referred to as belonging to the APUD »
series, the peptide honaone-producing cells being classified by , j
letter within this series. ij
The diolecystokihih-producing cell has been shown to correspond '
clodely to the intestinal Ï cell (Burra, Golcia and Go, 1D76; Polak,
Pearse, Bloom, Buchan, Rayford and Thompson, 1975) and is now 
generally accepted as being the X cell.
A4.4 Catabolism of Cholecystokiniii
Studies on the catabolism of cliolecystokinin arc at present 
incomplete. It has been shown that the disappearance half life of 
exogenously administered cholecystpkinin was 2*4.min. in man and 
2,6 uiiii. in dogs (Rayford, Hiller and Thompson, 1976) ,
Use of - Ï-CCIC has .shovm the sites of tissue uptake and 
catabolism of cholecystokiniii to be the kidneys, liver,, stomach, 
intestine, pancreas, gall-bladder, lungs and spleen, with a 
circulating half life of 3 minutes (Go, 1978; O'cyyang, Hg and Go,
1976). Eight minutes after injection the kidneys had concentrated 
about half the labelled cholecystokiûin injected^ This suggests 
the kidneys play a major role in cholecystokiûin catabolism and it 
is not therefore surprising that’ Go (1978) and Owyaug, Go, BiMagho,
Hiller and Brennan, (1977), using their radioimmunoassay found 
elevated serum levels of cholécystokinin in patients entering renal 
failure. . ' -.a.'
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Chapter A5
Relationship of Cholccystokinin with other Gastrointestinal Hormones 
A5.1 The Cholécystokinin Family
Structural similarities between the peptide hormones of the 
gastrointestinal tract divide .them indisputably into families.
The cholécystokinin family at present consists, of only four naturally 
occurring peptides (excluding variants and fragments); cholécystokinin 
gastrin, caeruiein and phyllobaeruleiu, ; Of these four only, 
cholecystokiûin and gastrin have been shown to occur in the human, 
caerulein and phyllocaerulein being extracted from the skin of the 
Australian frog llyla caerulea (DeCaro. Endèan, Ersparner .and - 
Uoseghini, 1968) and the. South American amphibian .Phyllornedusa 
Mauvagei (Auastasi. Bcrtaccini. Cei, De Caro,. Erapamer and. Impicciatore, 
1969) respectively.
The structural similarity is in the carboxy-terminal end of the 
molecule, the last five amino acids at this end of the.molecule being 
identical and the resemblance continuing with only minor variations 
to the residue: see Table 1. '
A5.2 Structure, activity relationships
rlany biological actions 6£ both gastrin and .cholecystokihin are 
produced by the C-tcriiiinal tetrapcptide ..amide (Tracey, find Gregory , .
1964; iîorley, 1270), hovjcver Ondetti ct al (1970) found the shortest 
sequence with a significant amount of cliolecystokinin activity to 
be the heptapeptide. The loss of the sulphate group from the
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heptapeptide was accompanied by almost total loss of activity, but 
this tyrosine sulphate group alone and with its : surrounding amino 
acids io virtually devoid of gall-bladder contracting ability. 
Maximum activity on a weight basis seems to be reached around the 
C-tefminal decapeptide which is 10-15 times as active as the whole 
molecule, with the C-taradnal octapeptide being 10 times ho active 
on a weight basis and 2.5 times as active on a molar basis as the 
full molecule (Ondetti et al 1970)*
The decapeptide caerulein also showed a similar potency while 
the movement of the sulphated tyrosine by one amino acid in either 
direction i.e. to positions or Gg (from C-terminiis) resulted 
in almost total loss of activity*
A5*3 The Secretin Family
The Secretin family consists of Tour structurally similar _ 
established polypeptide hormones; Secretin, Vasoactive Intestinal 
Polypeptide (V*I.P.), Glucagon and Gastric Inhibitory Polypeptide 
(G*1*F*) (iiacki, Greenberg and Bloom, 1978) sec Table 2 where 
points of identity are highlighted by boxes.
5S
m'i
H
>I
p!
H
O
S
en
NI
3aü
.34Jg&I«D,0
s•H4J
1MI0)I
4JW
«}
< I aH
W
3
co w2
00 w
«n
r-«
cm
ri
mcmN
tHm8
Cftess
es
a
00
es
S
II
q)
<
es
y£>
w
es
en
CM
es 2C5J
aH
U I 154HO P4H>
fis gH
i i P4 04O to M MPO how O O >
y " " " : : ' ; : ' : ' " ' .A5.4 Interreaction of Castrointestinal Polypeptide Hortaonaa 
A5.4.1 Choigcystokinin and Secretin
Since these two hormones share a cpncaon target organ, the 
pancreas, it Is not surprising to find evidence for their interaction: 
it appears that cholecyistokinin potentiates the action of secretin . 
on pancreatic bicarbonate output (Meyer, Spingoia and Grossman, 1971) 
for example an infusion of 0,25 CU/kg/hr of secretin in man produces 
half the maximum secretory rate, but when the same is given together 
with cholécystokinin maximum bicarbonate secretion can be achieved 
(Wormsley, 1969), (1 CÜ (Clinical IMit) of secretin is approximately
equal and equivalent to 4 Crick, Harper, Raper Units of 4 Ivy Dog Ikiits 
of secretin; 1 IDU secretin is defined as: that amount of dried
material in normal (0.9%) saline solution Which, when injected 
intravenously during 10 or 15s, will cause a 10 drop (0.4 ml) Increase 
in the rate of flow during a period of 10 min, the control or basal 
flow not being more than 1 drop in 2 min (Ivy and Janecek, 1959;
Harper, 1967)).
Although secretin itself has no effect on gall~bladder 
contraction (Berry and Flower, 1971)j there is some evidence 
(Stenind and Grossman, 1969a) that it may potentiate gall-bladder 
contraction stimulated by cholécystokinin, this effect, howevet 
may be pharmacological rather than physiological.
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A5.4.2 Cholécystokinin and Gastrin
In the cat (Way, 1971) and the rat (Chey, Sivasomboom, Hendricks, 
and Lorber, 1970) both gastrin and cliolecystokinin are able to elicit 
a maximal output of gastric acid, and although the molar concentration 
of cholécystokinin required was about six times that of gastrin, both 
hormones have full efficacy or are full agonists. However, in the 
dog (Johnson and Grossman, 1971) and probably also in man the maximal 
output of gastric acid that could be stimulated by cholécystokinin was 
only one fifth of that produced by gastrin. In these cases 
cholécystokinin is only a partial agonist for gastrin and has been 
shown (Grossman, 1971; Johnson and Grossman, 1971), to be a competitive 
inhibitor of gastrin, although it is unlikely that inhibition occurs 
at physiological concentrations.
Â5.4.3 Cholécystokinin and Insulin
Many studies based on thé use of impure preparation of chole- 
cystokinin have suggested that cholécystokinin stimulates insulin 
release thus contributing to the. greater rise in blood insulin 
following an oral load of glucose than the rise following an intra­
venous load. These observations have been well reviewed (Pfeiffer, 
Raptis and Fussganger, 1973).
However a more recent study by Hedner, Persson and Ursing 
(1975) found insulin to rise following injection of an impure 
preparation of cholécystokinin but not after injection of the purer
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hormone or the synthetic octapeptide. This, together with Harvey and 
Read’s (1973) observation that an oral load of magnesium sulphate 
elevated blood cholécystokinin but not blood insulin, suggests that 
cholécystokinin is not the powerful insulin releaser it was once 
thought, and that this action is far more likely to be due to the 
presence of G.X.P, in the impure preparations (Dupre, Ress, Watson 
and Brown, 1973).
SECTION B
BIÜASSAY OF CHOLECYSTOKININ
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Chapter BX
Background and initial manual technique
Bl.l Thé development of the superfusion technique
Superfusion of isolated tissues was first used by Finkleman 
(1930) to study the nature of inhibition in the intestine. His crude 
apparatus was heated by an external carbon filament lamp, and the 
muscle strips were attached to levers thus recording their contractions 
directly on to smoked drums. This was improved by Gaddum (1953) 
when measuring the effect of drugs on rat uterus, and the sophistication 
of a peristaltic punp to ensure a steady flow of superfusing solution 
was added eleven years later by Vane (1964).
SI,2 Application of superfusion to cholécystokinin bioassay
Sensitive bioassays for cholécystokinin began to appear in 
the late 1960’s, when the introduction of electronic transducers made 
this possible. The first (Amer and Becvar, 1969) made use of an organ 
bath; cholécystokinin was injected into the bath in increasing 
concentrations and a linear response noted up, to a concentration of 
40 mil11 Ivy Dog Units per millilitre of solution (m IDU/ml).
(An Ivy Dog Unit of cholécystokinin Is that amount of dry material 
which when dissolved in isotonic saline solution and injected 
intravenously in to a dog over 10 - 15s causes a 1cm rise in the 
bile pressure within 1 - 5  min (Ivy and Janacek, 1959).)
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This was quickly followed by the first superfusion technique 
for cholécystokinin (Berry and Flower, 1971), where isolated 
strips of rabbit gall-bladder were sùpérfused with whole blood from 
the portal vein of a cat, the blood was returned to the animal via 
the femoral vein. Apart from cholécystokinin a number of other 
substances were infused into the cat and the response of the rabbit 
gall-bladder strips noted. All the following were found to be 
without effect upon the gall-bladder strips: histamine, 5-hydroxy-
tryptaMhe, bradykinin^ prostagl^dins, E^, and , angiotensin, 
noradrenaline and secretin, at a concentration of l-5ng/ml. Adrenaline 
produced a relaxation of the tissue.
As a direct development from Bewry ,and Flovrer’s (1971) work 
caune the first truly in vitro superfusion assay for cholécystokinin 
capable of measuring cholécystokinin concentrations in human serum 
(Johnson and McDermott, 1973). This assay tested pentagastrin and 
the synthetic hexadecapeptide of gastrin and found no response by the 
gall-bladder, nor any potentiation or Inhibition in conjunction with 
CGK, ^ '
Bl.3. Early taaiiual superfusion assay for cholécystokinin in human serum 
Bl.3.1 Apparatus .
Some of the results to be presented later were obtained using 
this original technique. Basically the same as that used by Berry 
and Flower (1971) thé apparatus (Fig. Bl.l) consisted of two water baths
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Fig BÎ ,1 Apparatus for the original manual technique for the biodssoy of 
cholécystokinin.
maintained at 37 C» a peristaltic pnmp (Watson Marlow MIÎRE 22 with 
Delta head), an isotonic transducer and associated amplifier and chart 
recorder. ,/v. ,
One of the water baths held the organ chamber in which was 
suspended a strip of rabbit gall-bladder. One end of the gall- 
bladder was attached to a bent g.laes rod fimly^ anchored to the side 
of the bath, the other end of the gall-bladder was attached to the 
isotonic transducer (C.P.Palmer (Searle Diagnostics) High Wycorfce) 
fixed directly over the Organ chaWier so that the tissue in the organ 
chamber was below the level of the warming water outside and the lever 
on the transducer was held horizontally or very slightly inclined at 
the point of attachment (see Fig. bl.l).
From a 250ml reservoir in the second water bath Krebs balanced 
salts solution (see appendix A for composition), saturated with oxygen 
by the continuous bubbling through it of a mixture of oxygen (95%) 
and carbon dioxide (5%), was superfused over the rabbit gall-bladder 
strip in a closed circuit at a rate of 8-10ml per minute. Heat 
losses during passage of solution between the reservoir and the pump 
were compensated for by the inclusion of a short glass coil contained 
in the same water bath as the organ charrber and situated just before 
the nozzle applying the solution to the suspending cotton above the 
tissue. All the connecting tubing was approximately 2mm internal 
diameter.
F M
GALL
BLADDERCUT I. CUT 2.
CUT 3.
Fig 81 ,2 Preparation of rabbit gall-b ladder for superfusion
-GLASS RODNOZZLE
g a l lBLADDER
KREBSSOLUTION —
Fig 81 .3  Close-up of tissue undergoing superfusion
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31.3.2 Preparation of rabbit gall-bladder
À male New Zealand % i t e  rabbit weighing approximately 2.5Kg 
(Osefui range 2*“3*5Kg) was killed by injection into the ear vein 
of 2.5ml - Èxpirpl* (2o6mg/ml Phenobarbitone Sodium, Abbott Laboratories 
Ltd., Kent). The gall?bladder was immediately removed, drained of 
bile and immersed in o^gehated Krebs solution. %'^iie still iraaeraed 
the gall"*bladder was cut from the neck to the apex on both sides, 
opened out, scraped free of clinging bile and cut longitudinally into 
two strips (see Fig, 31,2), One strip was placed into fresh oxygenated 
Krebs solution, covered, and stored at 4^C for use next day.
Lengths of cotton (approx 4“ and 15") were attached to the ends 
of the remaining gall-bladder strip, Tiie short length was attached 
to the end of the bent glass rod and pulled through to leave only 
of cotton between the tissue and the glass rod; the excess cotton was 
removed and the glass rod attached to the water bath. The other 
thread Was carefully passed through the V of the superfusing npzale 
(see Fig* Bl,3) and attached to the arm of the isotonic transducer, 
leaving the gall-bladder strip suspended in the organ chamber so that 
it was in no danger of catching on the sides of the chamber or it* 
supporting glass rod, and was being evenly superfused with warm 
Krebs solution.
The first 3pml of superfusing solution to pass over the gall­
bladder Strip was allowed to run to waste; thereafter the tissue waa
allowed to equilibrate with the recirculating solution for a minimum 
period of ninety minutés. , -
B.1.3.3 Preparation of Standards
Four preparations of ehoiecystokinin were available for use 
as ^ standards! ^1) Fancreo&ymin (Boots Pure Drug Co.) in vials of 
approximately 100 Crick harper Raper Units (25 IDU), (il) ,Choie- - 
cystôkinin (Gastrointestinal Hormone Research Institute^ Karolinska,
Sweden) in vials of- 75 IDU, (these preparations contain approximately O.IZ- 
and 10% cholecystbklnin respectively), (iii) 99% pure cholécystokinin f 
(gift of Ftofessor V, MUtt,, Mediciiiska; Hobel Institutet Biokemiska Aydel- 
ningeh, Kàrolinska Institutet, Spluavagen 1, Stockholm, 104-?0i-60),
500 ug (rated activity 3000 XÜÙ/mg) redispensed in viala of I ug and 10 '
ugf. lyophilxsed and vacuum sealed in this laboratory, , (iv>. the >
synthetic octapeptide of cholécystokinin (gift of Dr. M. Ondetti, Squibb 
â Sons, Inc., Princeton, New Jersey), 2 mg with declared activity of 22,000 
IDU/rag, reduced by serial dilution and stored lyophilised in vacuum 
sealed vials, containing 625, 62iS, 62.5 IDU ehoiecystokinin activity.
In practice libst assays were performed using either Boots Pancreozymin 
or the synthetic octapeptide as standard. However at some time all four 
preparations were used for the assay had vials of each were diluted 
with Krebs solution in the following manner to give stock solutions /
containing 125 lalDU/iog; ■ • '-\
i) PancreozyminÎ vial containing 100 OHR units pancreozymin activity 
contents dissolved in 20ml Krebs solution; 5ml of this solution 
diluted to SO ml giving a staWard solution of 125 mIDU/ml.
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ii) Cholécystokinin: 75 IDU dissolved in 25ml Krebs solution;
2ml of this solution diluted to 50ml giving a standard solution of
120raIDU/ral.
iii) Ijjg 99% pure cholécystokinin was diluted to 25ral with Krhbs 
solution, giving a standard solution of 120mIDU/ml,
iy) 570^g synthetic C-termlnal octapeptide of cliolecystokinin
dissolved in 20ml distilled water.
Irai portions of this solution dispensed into snapules 
lyophilised and sealed under vacuum. Each vial contained approx­
imately 625 IDU cholécystokinin activity,
vi) The contents of one of these vials dissolved in 10ml distilled 
water.
vii) 1ml portions lyophilised arid sealed as before, each vial 
contained 62.5 IDU cholécystokinin activity.
viii) Tlie contents of one of these vials further subdivided into 
io vials each containing 6.25 IDU cholécystokinin activity.
ix) The contents of one of these final vials dissolved in 50ml 
Krebs solution gave a standard solution containing 125raIDU 
cholécystokinin activity per millilitre.
All the vials were stored at -20°C until required.
For calibration of the gall-bladder strips 0.1, 0,2, 0.4,
0.6, 0.8 and Irai of the standard solutions (i) and (iv) diluted to 
25ml gave solutions containing 0.5, 1, 2, 3, 4 and 5mIDU/ral, Using 
solutions (ii) and (iii) slightly more of the original standard solution 
was needed for the same effect.
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The conversion factor used throughout this thesis for changing 
Crick Harper Raper units into Ivy Dog Units was 4 CHR units 2  I 1*D. Unit, 
based on data in Table 2 of the paper by Professor Jorpes (Jorpes. 1968), 
This despite the statement in Martindale : The Extra Fharnacopoeia 
p.474 that the British manufacturers state that in the case of their 
product 1 CHR ^  1 X.D Unit, This would seem to explain fully the 
findings, in Chapter B4, but it would seem more likely that the methods 
of assessing the biological activity of each batch of cholécystokinin 
or pancreozymin by the two commercial manufacturers are in fact incompatible 
and one of their fundamental definitions is wrong.
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Bl.3.4 The Standard Heal; Preparation of patients and sampling times
In order to study the release of cholécystokinin and to determine 
any differences in levels of serum cholécystokinin in different clinical 
conditions and to note any changes following surgical correction of 
these conditions a standard procedure for blood sampling was laid down.
Patients were fasted overnight (nothing to eat, drink or smoke 
from 10 p.m.) for test at 9 a.m. the .following day. Samples of 
venous blood were withdrawn from suitable arm veins with tourniquet 
application through a 21 gauge needle.
An initial fasting sample of blood was taken. The patient was 
then fed a standard fatty breakfast consisting of; two rashers of 
bacon, fried; one egg, fried; two slices of bread; butter and 
marmaladeaand one or two cups of tea or coffee with sugar to taste 
(Fig, B1.4). Patients were asked to consume this meal within ten 
minutes if possible. Host finished the meal; some were not able to 
do so but Wore not eliminated from the series.
Timing began with completion of the solid portion of the meal 
and further blood samples were taken 10, 20, 30, 60 and 120 minutes 
after completion of the meal.
In many caseS the whole experiment was repeated approximately 
four weeks after the patient’s operation after the patient’s system 
had fully adjusted to the new conditions.
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Bl.3.5 Blood treatment
Initially all blood samples were 10ml in volume, in later 
experinoents the initial fasting sample was increased to 20ml, other 
specific experiments took different amounts.
The blood was dispensed in 10ml amounts into plain glass tubes 
(in later experiments these tubes contained 10,000 Kallikrein 
Inactivator Units (ÎC.I.U.) of (Trasylol) aprotinin. Once the blood 
had clotted the tubes were centrifuged at lOOOg for 10 rains, and the 
serum removed and stored at -20^C until required for cholécystokinin 
measurement.
Bl.3.6 Calibration and operation of the assay
Calibration of each gall-bladder strip began after it had been 
superfused with the recirculating Krebs solution for a minimum of 
ninety minutes and, with a steady base line on the recorder, was 
judged to be in equilibrium with the system, Standard solutions 
were prepared immediately before use from the stock solutions described 
above; in most instances this was the Boot’s Pancreozymin,
1ml of the stock solution (125raîDlî/ml) was diluted to 25ml with 
Krebs solution; final concentration of cholécystokinin was 5mîl)îl/ml,
Til is was warmed to 37^G alongside the reservoir of Krebs solution for 
4 wins during ifhich time the oxygen (95%)/ carbon dioxide (5%) mixture 
was bubbled through it. Tlie supply tube was then transferred from the 
Krebs reservoir to the standard solution, hhen the system was full 
of standard solution the return tube was also transferred to the vessel
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Fig Bl .4  Standard meal given to patients
holding the standard solution. Care was taken to see that no standard 
contaminated the main reservoir and that the standard was not diluted 
further by premature transfer of the return tube, a little of each 
solution being allowed to.run to waste..
The standard solution was recirculated over the gall-bladder 
until the contraction reached a maximm (plateau on the recorder), 
the delivery tube was then replaced in the main Krebs reservoir and the 
return tube moved to a waste receptalcle. Solutions were allowed to 
run to waste for 4 mins and Krebs solution was then recirculated for 
a further 4 mins or until base line was firmly re-established. The 
next standard was then introduced and a six point calibration line 
obtained by use of standards of 0,5, 1,22, 3, 4 and SralDU/ml. With 
some relatively insensitive gall-bladders the line was obtained with 
standards of 0.5, 1, 3, 5, 7 and lOmlDU/ml,
The average height (i.e. original base line to peak, and final 
base line to peak heights average) of each contraction due to each 
standard solution was plotted as a dose^response curve on linear 
axes. In the range of standards used the dose response curve was 
usually linear, (Fig, Bl.S) although occasional deviations from 
linearity towards S and log type curves were seen (Figs. B1.7 and
Bl.3/7 Measurement of cholécystokinin in human serum
Serum samples obtained and stored previously (1.3.5) were
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Fig Bl .5  Dose-response curve { linear ) to standard solutions 
of cholécystokinin
2 a4 6 100
Dose in mIDU CCK
Fig Bl .6 Dose-response curve (logarithmic ) to standard 
solutions of cholécystokinin
1 ,2  See notes under Fig 81 .7
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Fîg Bl .7  Dose-response curve (S-type) to standard solutions of cholécystokinin
1 Response throughout this thesis always refers to the 
height of the peak obtained on the chart recorder.
2 Dose throughout this thesis always means the concentration 
of CCK in m lDU/m l superfusing solution.
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defrosted by holding the tubes in a stream of warm running water.
Irai of each sample was diluted to 25ral total volume with Krebs solution.
This test solution was placed in the 37^C water bath with the 95%
oxygen/5% carbon dioxide mixture bubbling through it for.4 rains before
the assay supply tube was introduced, When the system was full of
the test solution the return tube waa also introduced to the
measuring cylinder and the test solution recirculated until a plateau
or maximum peak height was reached.
The supply tube was returned to the Krebs reservoir and the
solution allowed to run to waste for 4 rains; Krebs solution was then
recirculated until a steady base line was again obtained usually
a further 4 mins - and the next serum sample was then introduced,
ïlie height of the peak produced on the chart was measured.
This hheight was converted to ralhU CCK/ral test solution from the
calibration line already obtained. The amount of cholécystokinin
in the serum was then determined from the formulas
Serum CGK(raIDU/ral) « 25 x ralDU/ral test sample
ml serum diluted
For serum samples containing little or large amounts of cholécystokinin 
more (2-3ml) or less 0,25 - 0,75ml) serum was used for the test 
solution which was still made to a final volume of 25ml with Krebs 
,solution.
■' ; v ' ' -  - % ' . vf ., '
Chapter B2 Tlie :First Automation System 
B2.1 Introduetioa ,'v:
■ ' ■  .The- wajorityl of ■-■automated ■ aa'says -in régulai* use .rely upon\ à - //_ 
change in some measurable physical property occurring in a solution. 
However this change is produced# whethe by chemical or Other means, 
■■the-'final measurement -is^ o|f0n\ made ■with'-a.a'oiorimentric technique 
i) y not lag a ch ange in the in tans i ty of ;ab a Orb an ce or fluorescence, 
or a movement iii the wavelength of maximuia absorbàiiçe. Other physical 
properties. Such as a refràétiye index, may also he utilised. the 
outphts;’from .-these: ins trunènts' \are recofded-.permanently on charts ■ or 
digital print~outa from which the results àre calculated.
These methods are .frequently-: ado^ ted'.-'Where they arc needed to 
\,'proCé8aylargè numbers;of 'smallYsampies- quickly^and accurately or to 
: monitor. continuously the ■ effluent ; from a- columi, ; Often they are : more 
.'(efficient, thmi a. .manual -pro ces a; ;.as".- they ;'..c(m..'operate' ' continuously 
overnight - arid they rarely require more than a few ( Ip) millilitres
This .--assay'/differs.','from the,;, above in; thats (i) the physical : 
effect which ..'is (measuréd.-ia. a property of, a, biological tissue hot of 
a solution; (2) for - the .best 'results.cthe', maximum rate of process of 
. samples is four per hour, but three per hour is preferable; and 
(3): u sa«q)le voluam size uf 25ml .r 75ml is required depending upon 
'^eapparatus.: -- ,
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It is nevertheless an ideal system for automation requiring only 
a change from sample to wash in a regular manner similar to that provided 
by ah Auto Analyser sample changer, , The major problems to be overcome 
are the volume of solution required for each sample and intermediate 
wash, and the much longer time scale involved.
B2.2 The new system
The principle of the original assay was altered only in the 
substitution of an open system for the original recirculating system 
(Fig. B2.1),
The strip of rabbit gall-bladder was prepared and suspended 
from the transducer as already described (1.3.2). It was then 
equilibrated by superfusion with recirculating Krebs solution for 
a minimum of two hours.
A single standard solution containing SmIBU CCK/ml was first 
passed over the gall-bladder (original system. Fig. Bl.l) to determine 
the gall-bladder's sensitivity and the counter balance (the normal 
counter balance on the transducer was 1 paper clip SOOmg placed at 
the point of maximum leverage, for exceptionally strong (very sensitive) . 
or weak (relatively insensitive).gall-bladders, the counter balance warn 
increased to between 1| and 3 paper clips or decreased to I a paper 
clip respectively) required on the transducer. The amplification 
and recording systems were unaltered.
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Fîg B2.3 Circuit diagram for first automatic system
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Al l fur ther, s taudards and s amples were applied automatically 
from a modified 24-stàtion slide staining machine (British American 
Optical Co* Ltd* now leicliért-*Juhg ü*K.) (Figs, B2*l, B2.2- m d  B2*3) 
situated in an adjoining cold room maintained at 4^0. : .
Y Thirteen of the twenty four stations were supplied with 
the 95% dxÿgen/5% carbondioxide mixture through tubes attached to 
the machine by splints* . The sataple was collected through a second 
tube attached to the splint at the smmplih^^^ point* this tube being 
adjusted;ho that it just reached the bottom of the, sample containers*
The stations on the'madiiae-were';occupied;alterhately by_ vessels 
containing 75ml sample or standard and 500ml Krebs solution, respectively. 
The: machine was programmed so 'that^  négative''.pressure' from the sel^r 
priming peristaltic pump drew saniplé for five minutes followed by Krebs '. 
solution for 15 minute's^ . "
..•'The. slide staining mch,ine'required approximately - .3.0' seconds 
to change from One station to the next* During this time the probe 
was out of the solutions fpr about 16 seconds* A gap of this length 
of time had been previously seen to upset the response of the^  gall­
bladder to following samples*
The:';airgap. was /therefore' eliminated by thé ..insertion" Of a 
three-way solenoid valve (Dawrance Controls Ltd*,, Skeliaersdale,. Lance*, 
(now Dewraswitch Ltd*) Type 831443) operated by the slide, staining 
machiné ^(Fig;B2^3)* As the top of the machine lifted prior to 
moving to the next station, it lowered a small weight on to a micro- 
switch (Figé B2.2) energising thé solenoid and allowing Krebs solution
. ■ / Y Y ' Y k :  ' 1  ^ ' ; v - '  ‘Y -  '
from :a separate réserver ;lntd: the* system for the greater.-part ■ of the
time;-the probe-was not;, immersed;-V v "'Y
; 'y ■•Xo' .'guard .against. machine. dr; pump ; f ailure an alarm ays tern _.. ■, 
dependent" on .electrical:, capacity.' (Dielèetric constant). was- incorporated 
(FI-Monitor , Fispns Ltdi,) * Thé...timer dclaÿs the sounding of the
alarm for 8 seconds, thus spîàlivàirY bubbles Y'are-ignored* Y-',.:...
Y All equ.ipment-operated by raaihs .’electricity ,'waa'switched'of'f', , 
shortly after the "last saraple. had-beèrî'taken,'by an *ôffj only time 
,s w i t c h ;  ' y  /; / /  . J ' . , ' "  ' : /. / : '/
52.3 Opération of the automatic assay ' '
Following détermination of * the;, sensitivity of the, gal 1^ -bladder 
strip 02.2) and: completion of. adjustments to the court ter balance on i.Y 
tile,. transducer (range 250 - 1700 mg) and the position of the attenuator.. ' 
on "the .amplifier, the,;equipment was. ready.'to begin automatic 'processing-.i 
Thé 6 iidé s taiàing machine^ vas pro grsummed to run at three or 
/four'; samples-- per .hour-.r .-l.é*- to draw s;an#le for Ifive ' minutes - then,"wash 
for ten or fifteen;minutés according to thé speed with which the gall­
bladder relaxed following stimulation'.
'.'f.'".The gall-bladder was first calibrated in'a'similar manner to the 
manual technique, sample solutions containing 0.5, Ig 2, 3, 4 and 5 . 
mlDb^l CGK being *applled consecytively to the gall-bladder.; , Sérum , 
samples, generally. 2ml serum diluted,:to 15ml followed.
Twelve standards and samples could be measured during the normal 
working day* The machine could then be réset, the wash reservoirs 
refilled, and a further 12 solutions «wasured during the evening, the
-'Y/.'. Y Y ‘Y "  Y  -Y - «■ .rT,-- 4 0  •— ;■■■< ... ; ' " ' Y \  . ' ; 'Y-:,:
' trace ■being/examined thé héxt; .day.,' Y A n , loff only*. time' switch .-turned 
off ali mains electricity operated equipment shortly after the last 
à a m p l é ' ; h h é Y b é c n . ^ ' m e a s u r e d . . . ^'.Y;. Y . - " Y ; . '  ' . "- % : . % / / r-Y. ' Y
.The viabtY four'■samples'were usually.; standards'; .ensuring vthntv -
sensitiyity yariations were taken.into account in the calibration of 
results (formula see 1,3,7) ,.'Y'"iRleY slightYcarry over {6f : èné/sample 
to.'-:-thé next WAS n o t found, to be sufficient'*; ^ even'.Tîh en ^ -moving'from a 
solution of high cholecystokiniti concentration to one.of îoÿ chqle- 
cystok Yinin concentration, to affect the response of the gall-bladder 
to thé following solution. It was however desirable that this should, 
if possible, be eliminated,- ' '■ 'Y'.  ^ •
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Chapter B3 Development of the Automatic System 
B3»l Stimulus for development
The autoomtic system described in Chapter B2 was a major 
advance over the old manual technique and two advantages were 
immediately obvious: (i) the cholecystokinin content of twice as
many samples as before could now be estimated in a single day, that 
is 24 instead of a maximum of 12 in a normal working day; (11) the 
person operating the equipnmnt was released, once all the solutions 
had been prepared and positioned on the machine, for further useful 
work elsewhere, needing only to reset the machine with a further 
twelve samples at the end of the day. Results were worked out the 
following day.
With improved efficiency came an increased demand for 
^olecystokinin measurement, until a backlog of samples once again 
began to accumulate and an increased capacity was once more an 
obvious need, but how to achieve it?
Use of all 24 stations on the slide staining machine as sample 
positions, with Krebs wash solution coming from a separate reservoir 
was the most logical development and ways to do this were immediately 
explored,
B3.2 The second automatic system
The first design of apparatus to use all twenty four stations 
on the slide staining machine as sample positions is shown in Fig, B3,l,
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The slide changing machine was prograimaed to change station every 
five minutes. When the slide staining machine came to a station the 
relay coil was activated through operation of the microswitch, the relay 
contacts RC^ and RC^ then supplied power to the slide staining machine 
and the solenoid valve. In its energised state the three-way valve 
allowed sample to go to the gall-bladder; when de-energlsed Krebs 
solution from a separate reseryoir was fed through to the gall-bladder.
After sample had been drawn for five minutes the slide staining 
machiné began its changeover process. As the top of the machine 
lifted it operated the microswitch and cut off power to the relay coil 
and hence to itself and the solenoid valve. It remained suspended 
between stations while the interval timer (type STF3TMP 30 min.), 
activated by operation of the microswitch, ran for a predetermined 
length of time; 10, 15 or 25 minutes for 4, 3 or 2 samples an hour.
At the end of this wash period the timer contacts closed restoring 
power to the slide staining machine through contacts RC^. The slide 
staining machine then cockleted its station changing performance, 
operating the microswitdi again as it came to rest in its new position. 
This operation of the microswitch cut the power to the timer, thereby 
causing it to reset, and activated the relay coil thus giving power 
to the solenoid valve and itself through the relay contacts. The 
cycle was then repeated until all samples had been processed.
While the above system was theoretically correct electrically, 
and indeed was tried and proved on the laboratory bench, it was found
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to be of no practical use. The single reason for Its failure was the 
refusal, «hen positioned in the cold room, of the slide staining machine’s 
clock to restart at the beginning of each cycle. For this reason alone 
another system had to be designed.
B3.3 The third automatic system"’T»’"*'*"  ..       .
In the light of the above experience it was clear that any design 
for a system to use all twenty four stations on the slide staining 
machine would have to ensure that the machine itself was running 
continuously. With this in mind a third automatic system was designed 
(Fig. B3.Z).
Ëleetricâlly simpler than system 2 it still used the same 
electrical components. This time, however, the number of settles 
per hour was programmed on to the slide staining machine rather than 
through the timer.
The operation of this system is best described by observing the 
events of a station to station move; as the top of the slide staining 
machine lifts it operates thé microswitch, this disconnects the timer 
and causes it to reset, the circuit to the solenoid valve would 
therefore be restoted if the simultaneous operation of the relay had 
not broken the circuit at a second point (BLC)^ Reaching the new 
station the microswitch is returned to its original position activating 
the timer, deactivating the relay coil and thereby energising the 
solenoid valve and allowing sample to flow to the gall-bladder. Five
1
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Fig B3.4 Final arrangement of apparatus for the automatic bioassay of 
cholecystokinin.
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minutes later the timer switchea off the solenoid valve and Krebs
solution is allowed to wash over the gall-bladder for 10, IS or 25 minutes , >
according to a sampling rate of 4, 3 or 2 samples per hour respectively.
At the end of the wash period the slide staining machine moves to its 
next station and the whole cycle of events is repeated until just after 
the làst sample has been processed when an ’off only’ time switch cuts 
the power to all equipment operated by mains electricity. '
Both this system, and system 2, allowed a small amount of
carry over of one sample to the next, This although undesirable, did
not appear to affect the results adversely.
B 3.4 Final developments
Although, as has been stated above, the ’carry over’ from one 
sample to the next was small and apparently did not affect the results, |
it nevertheless remained a possible source of error which should, if i
practicable, be eliminated. r  :• j
The discovery and purchase of a four way solenoid valve v
(Dewraswitch Ltd., Skeltnersdale, Lance, type 8342A1) together with an 
additional timer (type STPYHP 72s, Î.M.O. Controls, London.) made ■ ; !
this possible. Tlie circuit diagram.is shown in Fig. B3.3 and thé final I
arrangement of the apparatus in Fig. B3.4,
Again it was the slide staining machine that was programmed to 
determine the number of samples per hour, and its movement from one 
station to the next that controlled the electronics. The changing of ;-|
the slide staining machiné from one station to the next reset and then  ^ 1
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restarted the two electric timer#. Timer 2 delayed energising the 
solenoid valve until the sample had reached and filled the valve 
(Approximately 45s), this avoided a long sir gap between the Krebs 
wash solution and the sample solution. Timer 1 switched off the 
solehoid valve after it had been energised (allowing sample to pass 
over the gall-bladder) for five minutes. In its de-encrgised s ate 
the valve allowed Krebs solution to go to the gall-bladder, any remaining 
sample being pumped to waste. In this way any carry over of one 
sample to the next was prevented.
a further refinement the supply line to the gall-bladder 
was split between the valve and the pump and both sample and wash 
solutions were fed through a parallel line to another set of apparatus. 
Thus the effect of a single sample solution could be observed 
simultaneously on two gall-bladder strips in parallel apparatus. The 
two gall bladder strips often responded very differently to the same 
dose of cholecystokinin, but each gall-bladder strip had its own 
dose-response curve from wîïich the cholecystokinin content of serum 
samples could be calculated.
With every station on the slide staining machine now used as 
a sample position, it was possible, having already processed up to 
twenty samples, for the machine to be reset with a full (24 samples) 
load to run overnight. It thus became practicable to estimate at 
least 40 cholecystoKinin-containing solutions in duplicate everyday.
All equipment operated by mains electricity was switched off by the 
’off only’ time Switch when the last sample had been processed some
r.'::"4.
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8-^9 hours later. This capacity for a theoretical maximum of 
48 samples, with 96 individual results per day turned a technique 
that was purely a research tool into something more practical and 
nearer the needs of a routine laboratory.
S3.4.1 Sample preparation
Using tV70 sets of apparatus in parallel it was found that 
75ml of sample solution was insufficient. The sample size was 
therefore increased to 100ml; 0.2, 0.4, 0.8, 1.6, 2.4, 3.2 and
4.0ml of the standard stock solutions (1.3.3) giving standard 
solutions of 0.25, 0,5, I, 2, 3, 4 and SralBU/ml CCK respectively 
when diluted to 100ml. Test samples of serum were prepared by 
diluting 2ml of serisa to lOOml; this only rarely resulted in a 
sample either too weak or too strong in cholecystokinin to obtain 
a result from the calibration line.
B3.4.2 Published material
Details of two of the automatic systems have been -puMl shed 
(Marshall, 1976; Marshall, Egberts and Johnson, 1978)ë
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Chapter B4 Standards; Invéatigatlon of Potency 
B4.1 introduction
Preliminary reports by Oliver and llarvey (1977) and Oliver^ Rey 
and Harvey (1978) have shown that coimaercial preparations of cholecystokinin 
from the Boots Company are up to eight times as activeaas preparations
'■'3produced by the G.I.H. Research Institute, Karolinska, when both :'A
preparations are diluted to give the same theoretical concentration of : ||
cholecystokinin in Ivy Dog Units, Their experiments showed conclusively ; 4
that Boots pancreozymin consisted primarily of ,small activemolecules u
and thé Karolinaka cholecystokinin to be mainly composed of the full , vi
33 or 39 amino acid molecules. However, no evidence was offered to ' Aj
show which of the commercial products was correctly calibrated, d
We had experienced difficulty^ in obtaining dose-response curves -
using the Karolinska cholecystokinin as standard, and routinely used 
either Boots paacreoaymin or the synthetic C-terminal octapeptide whose 
activities were consistently comparable. '
This study, inspired by questioning the relative activity of '-W
two different batches of Karolinaka cholecystokinin, and completed on  ^il
the 12th February 1978, tried to establish which preparation had been . f]
^correctly'calibrated* "'"'M
B4.2. Materials and methods
The stock solutions of each standard were prepared as previously 
described (section Bl,3.3) and the experiment perfornaad with the final 
automatic apparatus (section g 3.4). I
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Each scrii> of rabbit gall-bladder was first primed (see section:B6.9), 
by the passage of two seriua saiaples (Marshall* Egberts and Johnson* 1978) * 
the three .types of cholecystokinin (Boots Pancreozymin, Karolinaka / '
Cholecystokinin* and the, synthetic C-terainal octapeptide of cholecystokinin) 
Were then presented to the gall-bladders in graded doses* 0.5 -.20 mIOh/ml* 
i>fepared by dilation of the standard stock solutions, described above, , '
at a rata of , 3 oir 4 samples per hour. In one experiment the two batches 
of Karolinska Choie cys t bk in in were tested, for comparable activity.
The response of the.gall-bladders to each sample was recorded as 
the height of the peak (in cm.) on :the recorder attached to the isotonic ' /
transducers... Results were displayed as doserrcsponse curves. '
B4.3 Results
The actual peak heights recorded are depicted in Tables B4.1 - 
B4.3 and Figs. B4.1 and B4.2. (gee also Figs. API - AP6 in Appewdiac D). . .
The responses obtained from the three.types of cholecystokinin showed 
clearly that the Boots Pancreozymin preparation had between two and seven 
(mean 4.23) times the activity of the Karolinska Cholecystokinin as determined 
by the difference in the slopes of the dose-response curves for the 
two preparations. The activity of the octapeptide fell between that !
of Boots Pancreozymin and Karolinska Cholecystokinin, while no real _ _ , "
difference was detected between the two batches of Karolinska .
Cholecystokinin. f :
B4.4 Discussion
While preparing the standard solution of the octapeptide of cholecystokihia 
it was noted that the machine vised for dispensing 1 ml
F P4U
TABUS B4.1
Test for egulvAlence of activity in two batches of Karolinska Cholecystokinin
Batch No dosé Response 6£ gall-bladder in qm Boots Pancreozymin
applied gall-bladder gall-bladder equivalent in MXDU/ialmIDÜ/ml A É A B Mean
27742 0.25
0.5
1.0
2.0
0.9
1.1
1,2
1.6
1.75
1.9
1.7
1.8
0.3
0.5
0.575
0.9
1.6
1.75
1.55
1.65
0.95
1.125
1.063
1.275
27725 0.25
0.5
1.0
2.0
1.2
1.2
1.4
1.5
1.5 
0.9 
1.1
1.6
0^575 1.375 0.975
0.575 0.8 0,69
0.8 1.0 0.9
0,875 1.475 1.175
;r:-i
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TABUB B4.2
Testing the relationship between two coimercial preparations
of CCK
Teat Solution Gall-bladders response Test Solution . Gall-bladders reap<
in mIDU/ml in cm in cmA B A B
P 6,5 0.2 0.1 P 5.0 3.3 0.9
P 1.0 0.2 0.2 P 7,0 3.6 1.4
P 2,0 0.6 0.2 P 10.0 4.6 1.35
P 3.0 1.3 0,4 P 10.0 + K 10.0 3.9 0.7
P 4.0 1.7 0,4 P 7,0 + K 10.0 3.7 0.6
P 5,0 2.2 0.5 P 5.0 + K 10.0 3.0 0.6
K 15.0 2.3 6.3 P 3.0 + K 10.0 2.5 0,4
K 10.0 . 1.6 0.2 F 1.0 + K 10.0 1.4 0,3
K 5.0 0.7 0.1
K 3.0 0.5 0.15
K 1.0 0.2 0.1
K 0.5 / 0.15 0.1
P 1.0 0*75 0.2
P 3.0 2,6 0.7
Pancreozymin *■ P 
Karolinska " K (batch 27725)
FF4i.3
TABLE B4.3
Testing the relationship between three preparations of CCK
Test Solution Gall-bladders response Test Solution Gall-bladders response
in mIDU/ml in cm in cm
A B A B '.r:l
OP 0.5 0.6 6.5 P 0.5 . 1.7 : 0.7
OP 1 0.9 0.7 P 0.5 + klio 3.6 1.5 yÿl
OB 3 2.15 . 1.0 P I  + K 10 4.6 - 2.5 . #
OB. 5 . ; 3.5 1.4 P 2 + K 10 r /:)6.4 - 3.e . f
OP 7 4.9 2.4 P 4 + K Ï6 : y:;Cr7.6, .5.1 i;|i
K 0.5 0.3 0.2 P 5 + K 10 ; 8.3 1
K 1 0.5 . 0.4 P 7 + K 10 ; ^ 8.7 7.0
K 3 0.6 0.7 K T . ; . /:T.4 .
1.2 1.0 K 3- ..g:'-/:2.5 0.4 -1#
K 10 2.8, 1.85 " '' .'K 5 - 3t4
k 15 3.9 2.9 K 7 '. - 4,4 1.1 •
K'20 6.5 4.2 K 10. r 5.3 . - -
P 7 6.7 6.0 p 10-/-.:: 13/0^ 8*7
■' ? 5 6.5 4.2 P 7 10.1
P 3 ' /5.0 2.1 p 5 9.3 -5.0 ,.@|
P 2 4.0 1.6 \P 3 -Vi-8. 6 3.5 - g
P 1 2.3 0.8 p.:2 ' . 7.2 2.0
4.8
Pancreozymin « P P 0.5 , . 4.0
Karolinska • K (batch 27742)
Octapeptide - OP
B " Estimate, top of peak off chart
.i
::.:v
 ^ . :  -  ■ ■ \  -1^
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portions at each stage of the serial dilution (Corapùpet, General â
Diagnostics Ltd;) was in fact delivering very slightly less than 1ml.
With the very large dilution factor involved - 1:10 at final stage - 
it would not.be surprising to find that small dispensing and dilution 
errors have crept in and been magnified so that the actual activity in 
the final solution is lower than calculated^ the above observation 
makes it most unlikely that these errors would result in an activity f
higher than expected.
It is therefore logical in view of the evidence of Figs. B4.l,
B4.2 and API - AP6 to conclude that the pancreozymin activity reported 
by the Boots Company on their vials is correct* The fact that the 
logarithmic curves do not reapy appear (though this has not been 
tested statistically) to differ in parallelism is an indication that 
the same substance is being measured each time at considerably different 
concentrations • With thé number of points on each curve limited to *
six it is unlikely that the apparent deviation from parallelism 
(Figs* B4*l and B4*2), when Boots and Karolinska preparations were 
combined is due to some form of competitive inhibition* Indeed in 
the face of Oliver and Harvey’s (1977) results* Boots retested their 
original standard* now 10 years old* in their cat system; they found 
no change in its activity (Harvey* private communication).
The discrepancy can only be explained by three assumptionss
(i) the assertion that 4 CHR units —  1 ID unit is wrong* (ii) the I
%
r: ' ' _  ' ' ; ,
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Karolinska assay system is producing high results causing incorrect 
labelling of the activity of their produce, or (iii) the shelf life 
of the Karolinska material is much shorter than claimed.
It does not seem likely that any Inhibitors are involyed, but 
this experiment does bring sharply into focus the question of wtiich 
standard should be used for a bioassay of cholecystokinin, and in 
what hnits the results should be e^qpressed, SmIDU is equivalent 
to approximately 250pg (28pmol) of the octapeptide (22,OCX) IDU/mg, 
Ondettl et al, 1970) but would be l,7ng (43pmol) of the full molcciiie 
(3,000 IDtf/mg, Jorpes and Mutt, 1968), Centres using different 
standards will therefore get different results for the same unknown 
and the discrepancy could bé exaggerated further by the use of different 
units, with a different base, to e^H^ress the result.
However, since it is still impossible to be certain which 
melecular form of cholecystokinin is responsible for the greater part 
of the activity in serum it is probably pointless to try m d  express 
results in any way other than biological units.
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Fig 8 5 . Î Comparison of results obtained by radioirnmurio and 
bioassays for the amount o f cholecystokinin in human serum 
samples^ using linear scales
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Chapter B5 Compariaon of Radioimmuno and Bioessaye for CholécystoHlnln 
B 5 ♦ 1 In tr odti G t ion
While the development# described Its the preceding chapters were 
taking place I was in cont act with a group of workers in Bris til ttho were 
also interested in cholecystokinin> but who were at that time concentrating 
on the development of a radioimmunoassay (Harvey et al, 1974), It was of 
interest to both groups of workers to see if a correlation between the two 
very different types of assay could be established.
B5.2 Method
. Blood samples were taken from twenty volunteers, some fasting, some 
stimulated with milk or magnesium, chloride. These were divided evenly.
the serum collected and stored frozen at until required for assay.
Radioimmunoassay was performed by the Bristol group according to their 
established technique (Harvey et al. 1974), cholecystokinin bioactivity 
was estimated using the first automatic technique (chapter B2). Each 
centre performed the assay ’blind* without knowledge of the type of sample 
or the other centre’s results*
B5.3 Results
Results from this experiment are shown in Figures B5.1 and B5.2; 
when the results from the two centres were plotted on linear axes (Fig. B5.1) 
a non-linear relationship was seen, a small rise in radioimmuno activity 
initially corresponding to a large increase in bioactivity, then at high 
bioactivity levels a small rise in bioactivity corresponding to a large rise 
in radioimmunoactivity. This is typical of a logarithmic relationship.
i
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On performing a log - log transform a linear relationship between 
the two assays was established (Fig* B5.2); the regression line Had a high 
coefficient of determination (r ) of 0,625 and this is shown together with 
the 95% confidence limits*
B5*4 Discussion
That this experiment achieved its objective in showing a direct 
relationship between the results front the two laboratories was quite clear 
from Fig, B5,2, However, the intercept on the bioassay axis strongly 
suggested that the bipassay was measuring something which the radioimmunoassay 
was not. From the intercept the average value of this unknown substance 
was calculated to be approximately 28mIDU/ml for each sample.
To test this theory a Ami sample of a large pool of serum was 
extracted with dextran-eoated charcoal to remove all the small peptides 
including cholecystokinin (Morris and Morris, 1964), The cholecystokinin 
content of the extracted serum was estimated to be 31«IBU/ml, very close to 
the predicted 28mIDU/ml,
The finding of this residual activity, vhich was termed the ’serum 
blank’, was a bonus from this experiment.
Thus this experixaent succeeded in showing that results, from two widely 
separated laboratories, using totally different procedures to measure the 
same substance can bear a linear relationship to one another. That the
two assays utilised different units which were not readily interchangeable
- ' \  ' " ' ' . - did not matter, since the form of cholecystokinin in human serum, and
' ■' 'hence its molecular weight were unknown. Also unknown was the complete
I :
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Specificity of the radioimaunoassay for the different fragments of 
cholecyatokinin to which it was sensitive. Each assay had its own 
dose-respdnse curves from which the results were calculated, %nd these 
in their final form were what mattered.
The findings from this experiment led directly to the experiments 
described in the following chapter.
1
J
;:i
■?
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Chapter 86 Validation of the Technique 
B6.1 Introduction 
; Î Biarly experiroeois (dohhsbn and McDermott, 1973) gave unexpectedly 
high values for serum concentrations of cholecystokinin when ctmiparcd with 
values for other gastrointestinal hormones. Possible reasons for this 
discrepancy have now been investigated and the present experiments were 
designed to answer four main questionss
(i) IS the response of an Isolated .rabbit gall-bladder to a stimulus 
constant for the duration of the expêrismnt?
(ii) does serum itself affect the response of the isolated gall-bladder?
(iix) can cholecystokihin-moicking substances be isolated and removed?
(iv) can the apparent cholecystokinin content of à serum sample alter 
during processing and storage?
The final question has been asked because it has been shown (Ondetti,
Rubin# Engel, Pluscec and Sheehan, 1970) that some of the smaller 
carboxyterminai fragments of cholecystokinin may be up to seven times more 
active on a molar basis than the full molecule (e.g. C-terminal octapeptidc
2.5 times as active# C«terminal dodecapeptide 7 times as active). Hormonal 
activity normally drops during processing and storage of a sample but if 
enaymic breakdown of the full cholecystokinin m  lecule occurred, a considérable 
increase in cholecystokinin bioactivity could be generated before the 
activity of the aa#q>le was measured.
:  ^ , ■' ■ v: 1. - 3
-, j:
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B6 » 2 Procedures
These experiments were performed as a progression from each other, 
over a period of time as new thou^ts and questions came to mind. The
actual technique used for a particular e^eriment is indicated at the
beginning of the relevant paragraph*
It is not known ^ i c h  form of cholecystokinin is the active
constituent in serum, i.e. the full molecule or small fragments or a 
conèinatîoïi of both. It is therefore more meaningful to express results 
in terms of biological activity (mIDU/ml), although for comparison the 
molar equivalentoof the full molecule in nmol/ml has been placed in brackets 
after quoted biological units using conversion factors based on 3000 IDU/mg 
(Jorpès, Mutt and Toczko, 1968) and accepting the laolecular weight of 
cholecystokinin as 3940,
86.3 The effect of time
86.3.1 Method
Using the original manual technique (chapter Bl) to study the effect 
of repeated stimulation over a period of 12 - 14 hours, the responses of 
the isolated strips of rabbit gall-bladder to standard solutions of 
cholecystokinin containing 0.5, 1, 2, 4 and 8 mlDU/ml (0.04, 0.09, 0.17,
0.34 and 0,68 pmol/ml) cholecystokinin as pancreozymin (Boots) were sœasured. 
The solutions were repeatedly passed over the strips of gall-bladder in the 
above order. No serum samples at all were passed during these experiments. 
B6.3.2 Results
Figure B6.1 shows idie result of one experiment where standard
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concentrations of choXecystoîcinin were applied repeatedly for 12 •* 14 hours* 
Each line is a dose-^respouse curve to the five standard solutions introduced 
consecutively* Similar results were obtained with other strips of gall­
bladder* The slopes of the doe,e-response curves increased stehdily for 
the first 7 hours before stabilising* The slope of the final dosé-response 
curve in three experiments was found to be greater than the slope of the 
initial line by a factor of 2*29 + 1,295 (P<0.001 from t-test for
comparison of slopes) but the slopes of the last two lines were very similar 
<P>0,2) confirming stabilisation.
' The effect of serum
B6»4*l Method
lîaing the first automatic system (chapter B2) to observe the effect 
of normal serum on the responses of the Isolated rabbit gall-bladder to 
standard solutions of cholecystokinin# settles were superfused over the 
gall-bladder strips at a continuous rate of three samples per hour* A 
five point dose-response curve was obtained* Two consecutive safeties 
cohtaining 2ml human serum (stored froxen ât -20 C until required)> diluted 
to 75ml with Krebs solution* were then passed over the strip* of rabbit 
gall-bladder. The cholecystokinin doses were then repeated, further serum 
samples passed and the cholecystokinin dose# repeated again, ; In two 
similar experiments serum from blood treated with Trasylol (aprotihin, see 
section B6*6) was used.
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Fig B6,? Dose -response curves for cholecysfokinirY^ given os., 
mil Ii Ivy Dog Units/ml^showing the alteration in slope from the 
in itia l curve ( • )  to that after exposure of the rdbbit’ 
g all-b ladder to a single serum sample ( 4  ) which had not 
altered after 8h (o )  ,
B6»4;2 Results ,
ïhe effect of serum on the dose^response curve to cholècyetokinin 
in one out of five similar e^perfraenta is shown in Fig* P6,2j iimsediately 
after the passage of the first serum sample the slope of the cholecystpkiniu' 
dose-response curve increased by à factor of 2*75 - 1.058 ( F < 0*001 
from t-test for comparison of slopes) (cfë 2,29 see Fig, Bbil)/ over 
the slope of the initial dose-responsè curve* Further sérum samples did 
not alter the slope of the dosé response curve again; this remained 
stable for the duration of the experiment (12hr; P^0,2; five experiimnts). 
Trasylol made no difference to this serum shift effect; the ratios 
of the slopes of the lines were 2,5 and 2*6' in the two experiments.
86.5 Cholecystokinin — mimicking substances ...
86.5.1. Method .
Üsiiig the final automatic system (chapter 83,4) the possibility 
that lion-pepticlé .molecules in the serum ■were contributing to the 
cholecystokiiiin-like activity was tested'using charcoal to extract 
the pçistides from the sérum by adsorption (Morris,and Morris > 1964), 
leaving other active substances behind. An insolubilised spécifie 
antibody for cholecystokinin would have been preferable aiid left no 
doubt that only, cholecystokinin was extracted, this however* was not 
available* Blood samples (20ml) were taken from fasting volunteers 
The samples were dispensed into tubes containing 10,000 kallikrein 
inactivator units (KIU) of Trasylol per 10ml blood. When the 
blood had clotted the sérum was collected.
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The cholecyatokinin-llke activity was then estimated;
(i) For total cholecystokinin activity, 2ml portions of each serum 
sample were diluted to 100ml with Krebs solution.
(ii) For cholecystokinin-mimieking substances, 4ml portions of each 
serum sample were shaken with approxiraatoly 80mg dextran-eoated 
charcoal (lOg activated charcoal, HCl washed, Sigma; Ig Dextran 
T70, Pharmacia Fine Chemicals). The charcoal was removed by 
centrifugation at 1700 x g for 10 minutes and the extracted 
serum diluted to 100ml with Krebs solution.
To confirm that the charcoal was extracting cholecystokinin 
and peptides of a similar molecular weight, 25ml blood sauries 
were taken from four non-fasting volunteers. The samples were 
evenly distributed among ten plain glass tubes. Once the blood 
had clotted the tubes were centrifuged (1000 x g for lOmin.) and 
the serum removed and pooled. Portions of this pool of serum were 
then treated as follows:
(i) 2ml remained untreated (for total CCK activity),
(ii) 2ml + 125mXDU (10.5 pmol) CCK (pancreogyxain),
(iii)4ml extracted with dextran-eoated charcoal,
(iv) 4ml + 125mIDU (10,5 pmol) CCK extracted with dextran-coated charcoal
(v) 4ml extracted with dextran coated charcoal then digested with trypsin
(vi) 4ml extracted with dextran-coated charcoal, digested with trypsin 
then re-extracted with dextran coated charcoal.
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(vii) 4ial +125mIDU (10,5 pmol) CCK extracted with dextran-eoated 
charcoal then digested with trypsin,
(viii) 4ml + 125mIDlI (10,5 pmol) CC3C extracted with dextran-coated 
charcoal, digested with trypsin the re-extracted with dextran- 
coated charcoal.
Trypsin (treated with dextran-coated charcoal. Sigma) was 
prepared at a concentration of 2mg/ml in 1% aqueous ammonium 
bicarbonate and stored at -20°C until required. 2ml of this 
solution was added to each scrum portion to be digested and the 
reaction was allowed to proceed for 30 min. at 37°C when it was 
stopped by the addition of 10,000 KIU Trasylol, The treated 
solutions were stored at -20°C for 24 hours before measurement 
of cholecystokinin bioactivity,
B6»5.2 Results
Table B6.1 shows the quantitative removal by dextran-coated 
charcoal of both endogenous and exogenous cholecystokinin from 
serum. It also illustrates the good recovery of exogenous 
cholecystokinin and shows that digestion of extracted serum with 
trypsin does not release small fragments of cholecystokinin 
with additional activity.
It was found that, whereas the level of cholecystokinin 
in the serum of subjects varied after a meal, the amounts of 
chole cy s tokininrmimi eking substances remained small and constant 
(range 5-45 mlDU/ml serum; 0,4-3.8 pmol/ml), but the proportion
Tabla B6.1
Effect of extracting normal serum and normal serum with 
added Cholecystokinin (CCK) with dextran-coated Charcoal 
(BO mg), and digesting the extracted serum with trypsin and 
re-extracting the digested serum.
fPCo
Serum sample
mini Ivy Dog Units/ml 
serum (pmol/ml)
A Extracted
B Extracted
A Extracted,digested 
B Extracted,digested 
A Extracted,digested,re-extracted 
B Extracted,diges ted,re-extracted
141 (11.9) 
246 (20.8) 
8 (0.7) 
11 (0.9) 
7.5(0.6)
8 (0.7) 
7 (0.6)
9 (0.8)
A, Normal serum; B, normal serum + 125 mill! Ivy Dog Units (10.6 pmol)
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of these substances in the total cholecystokinin activity of 
the serum of any individual could not be predicted.
B6.6 Possible degradation during processing and storage 
B6.6.1 Method
Using the final automatic system (chapter B3.4) the 
possible effects of the experimental procedures on the final 
estimates of cholecystokinin activity were tested in several 
ways. First, 20ml blood sauries were taken from five fasting 
volunteers; 10ml blood were transfered to a normal plain glass 
tube as a control, and the other 10ml were transfered to another 
plain glass tube containing 10,000 KIU Trasylol. Both samples 
were treated in the same manner to produce serum and were then 
frozen and stored at -20°C for 4-5 days until examined for 
cholecystokinin bioactivity. Further experiments were conducted 
to observe the effect of Trasylol on the cholecyatokinin-mimieking 
substances. Samples of blood were divided into two; one half was 
treated with Trasylol as before, the other retained as control. 
These two samples were then further subdivided giving four 
measurements for each volunteer:
(i) control,
(ii) cholecystokinin-mimicking substances,
(iii) Trasylol treated.
iî
iI
y-y
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(iv) Trasylol treated choiecystokinin-mimicking substances.
To test the recovery of cholecystokinin added to serum, 
a 50ml sample of blood was taken from a non-fasting volunteer.
This was evenly distributed among five plain glass tubes each 
containing 10,000 KIU Trasylol. Once the blood had clotted, 
the tubes were centrifuged and the serum was pooled.
This pool of serum was divided into five 5ml portions; .
the first was to act as control, to the others were added 0.1,
0.2, 0.3, or 0.4ml respectively of a solution containing 1,25 
IDU/ml (10.5 pmol/ml) of cholecystokinin. Each portion of 
serum then had an additional 125, 250, 375 or 500 mIDU (10,5,
21, 31.5 or 42 pmol) cholecystokinin respectively. 2ml of serum
from each tube were diluted to 100ml with Krebs solution and ;
the cholecystokinin bioactivity was measured on two strips of
rabbit gall-bladder set in parallel.
Finally, to assess the effect of all factors, the levels 
of cholecystokinin in the serum of ten normal fasting volunteers
were measured with all four factors described above taken into . y
account (i.e. Trasylol added to blood samples, estimation of 
CCK-mimieking substances made, gall-bladders primed with serum 
before calibration) were measured, and the release of cholecystokinin 
in five patients following a liquid meal of ^Build Up* (Carnation) 
was followed for one hour. '
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B6.6.2 Results
The differences in cholecystokinin-liko bioactivity between 
serum control samples from five fasting volunteers and the same 
samples with added Trasylol are shoim in table B6.2, There was 
a very marked reduction in apparent cholecystokinin activity 
when Trasylol was used. Table B6.3 records the average of two 
estimations of cholecystokinin in blood samples from non-fasting 
subjects. This illustrates that while Trasylol appreciably 
affected the total measureable cholecystokinin, it did not 
significantly alter the ’serum blank’ (cholecystokinin- 
mimicking substances, P>0,2, paired t-test). The reduced 
effect of Trasylol on these samples (cf, table B6,2 was 
probably due to the non-fasting state of the volunteers (see 
Discussion), Trasylol did not alter the response of the 
gall-bladder to standard cholecystokinin (neither Boots 
preparation nor the octapeptide) in Krebs solution.
Table B6.4 shows that both satisfactory recovery of 
added cholecystokinin and a good correlation can be obtained 
from two strips of gall-bladder set in parallel.
After modification of the method (blood taken into 
Trasylol, measurement of serum blank, and priming of the gall­
bladders), the mean fasting level of cholecystokinin in the 
serum of ten young normal healthy volunteers was found to be 
28 + 10 mlDU/ml serum (2.4 + 0.8 pmol/ml); this was about one
FPé3,2
Table B6.2
Effect of adding aprotinln (Trasylol, 10 000 kallikreln 
inactivator units/10ml) to individual samples of human blood 
from five fasting volunteers on the concentration of 
cholecystokinin (CCK) in the serum.
mil11 Ivy Dog Units CCK after Trasylol
Serum sample CCK/ml serum (maol/tal) (% of control)
A Without Trasylol 190 (1.60)
A With Trasylol 13 (1.1) 6.6
B Without Trasylol 73 (6.1)
B With Trasylol 5 (0.4) 6.9
C Without Trasylol 150 (12.7)
G W ith Trasylol 11 (0,9) 7.5
D Without Trasylol 128 (10.8)
D With Trasylol 28 (2.3) 21.5
E Without Trasylol 78 (6.6)
E With Trasylol 20 (1.7) 25.6
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third of the level found before modification (Johnson and 
McDermott» 1973)»
Figure B6»3 shows the time course for the release of 
cholecystokinin following a liquid meal» It should be realised 
however that the sise and timing of the peak response varied 
considerably from patient to patient occurring as early as 
five minutes or as late as 60 minutes after ingestion of the 
meal; this has the effect of depressing the average response 
indicated in Fig* B6*3 and flattening the curve*
B6.7 Determination of the optimum amount of Trasylol to add 
to each blood sample 
B6*7*l Method.
30ml of blood was taken from each of three non-fastlng 
volunteers. Each sarq^le was divided evenly between three 
plain glass tubes containing 5000» 10*000 and 20*000 KIU of 
Trasylol respectively (0,25* 0.5 and 1ml of the commercial 
preparation of Trasylol, The blood was allowed to clot, the 
tubes centrifuged and the serum separated and stored frozen 
at “ 20^C until required. Each sample was then assayed for 
cholecystokinin bioactivity using the final automatic system 
(chapter 53.4) and two strips of rabbit gall-*bladder set 
in parallel.
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B6.7.2 Results
Table B6o5 shows the result of this experiment with 
the individual results obtained on the two gall-bladder 
strips A and B, Each portion of blood was assumed to yield 
5ral of serum. The total volume of the three test solutions 
from each blood sample was then 5,25» 5,5 and 6,0ml corresponding 
to 10ml blood treated with 5@000, 10,000 and 20*000 KIU Trasylol 
respectively.
The results from the three volunteers differed widely* 
from a reduction by a factor of approximately 3 in the amount 
of cholecystokinin bioactivity by 20,000 KIU compared with 
5,000 in two samples, to virtually no difference in the effect 
of the tî-70 amounts of Trasylol in the third,
10,000 KIU Trasylol effected soma reduction in activity 
in all cases and was adopted as the standard amount to be added 
to 10ml of blood. This amount (0.5ml) was felt not large enough 
to have significant dilution effects, but sufficient to inhibit 
at least some of the enzymic degradation during processing 
and storage.
B6.8 Discussion
The isolated rabbit gall-bladder increases in sensitivity 
to repeated standard solutions (section B6.3) of cholecystokinin
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over a period of about 6-8 hours after which it remains stable.
A single serum sample Increases the sensitivity of the gall­
bladder to its maximum immediately (i.e. equivalent to 6-8 
hour stimulation with standards* section B6.4). Both Figs.
B6.1 and B6.2 have a true zero and therefore direct cott^arlson
is possible. Thus a strip of gall-bladder can be *primed’
with an initial serum sample before determining the cholecystokinin
dose-response curve; its sensitivity will then remain unchanged
for the duration of the experiment and this can be confirmed
by passing further standards during and at the end of the
experiment.
Results in table B6.1 (section B6.5.2) make it unlikely 
that residual cholecystokinin like activity after extraction 
with dextran-coated cliarcoal is due to a high molecular weight 
cholecystokinin. We have termed this residual activity whose 
nature is unknown the 'serum blank*. Berry and Flower (1971) 
and Johnson and McDenwtt (1973) tested a number of substances 
including secretin* gastrin and 5-hydroxytryptamine; in addition 
we have also tested glucagon (5 and lOug/ml superfusing solution) 
and these substances alone and in conjuncfion with cholecystokinin 
had no effect on the response of the gall- bladder. The 'serum 
blank* is not a breakdown product of cholecystokinin as it is
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still present when Trasylol is used. At present the only way 
to eliminate the ’serum blank’ la to measure it and subtract 
it from the total cholecystokinin activity found in the untreated 
serum.
Trasylol reduced the cholecystokinin-1ike activity of the 
serum sample but not the action of cholecystokinin or cholecystokinin 
octapeptide on the strip of gall-bladder (section B6.6), Thus 
since Trasylol inhibits proteinascs which are activated in tissues 
damaged by ischaomia and hypoxia (for instance in shock or 
through tourniquet application, Glen and Lefer, 1972)* it is 
likely to be preventing the breakdoxm during processing of the 
full cholecystokinin molecule to the much more active dodeca™/and 
octapeptides•
The lowût cholecystokinln-1ike activity in serum treated 
xfith Trasylol strongly suggests that in its absence activity 
is generated in vitro. Since Johnson and McDermott (1973) found 
a slight loss of activity when repeated measurements xfere made 
on five consecutive days after deep freezing, it is likely that 
the increase in activity occurs during processing.
The effects of Trasylol are much greater on samples from 
fasting subjects than on those samples taken at the peak period 
after ingestion of food.
M <M>
lïx the case of the related hormone gastrin^ the high molecular 
weight G34 form predominates in the serum of fasting subjects, 
whereas the smaller G17 is released after a stimulus (Rehfeld, 
Stadil and Vikslsoe, 1974)« It Is possible that similarly 
significant amounts of the dodeca and/or octapeptides of 
choXecystokinin (which cannot be broken down further to more 
active fragments) are released after a meal, but are not present 
in the serum of fasting subjects.
l?Qur factors then appear to have contributed towards 
the surprisingly high estimates of serum choXecystokinin 
measured biologically in vitro.
(i) The sensitivity of the gall-bladder increases with the 
passage of time, early standards will therefore give 
artificially low values for the response of the gall­
bladder to that dose of choXecystokinin.
(ii) The passage of serum over the isolated gall-bladder 
immediately Increases its sensitivity to the maximum; 
a gall-bladder can therefore be ’primed® before it is 
calibrated and the errors due to (1) eliminated.
(iii) Substances mimicking cholecystokinin activity arc present 
in all sera and must be measured and subtracted from the 
total cholecystokinin activity.
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(iv) Unless an enzyme inhibitor such as Trasylol is added to 
the blood sample a considerable in vitro generation of 
cholecystokinin activity may occur.
However these factors apply to all samples and do not necessarily 
invalidate the relative changes in the same patient following a 
stimulus such as a meal»
B6.9 Conclusions
From these experiments it was concluded that, in the 
routine use of this method, the first three solutions of 
cholecystokinin presented to the gall-bladders should he:
(i) a medium dose of 5mIDU/ml (0,4 pmol/ml) of standard 
cholecystokinin in Krebs solution,
(ii) Two portions of 2-3ml pooled serum diluted to 100ml with 
Krebs solution.
The first solution gives an approximate idea of the sensitivity 
of the gall-bladder and will indicate if any adjustment of the 
transducer’s coimter-balance is required, and the second two 
ensure the complete resetting of the dose-response curve, that 
is priming of the gall-bladder before calibration,
A further dose-rasponse curve at the end of the run and 
a series of standard cholecystokinin solutions at intervals 
during the run should be used as an extra precaution. In addition, 
all blood samples should be taken into Trasylol (10,000 KlU/lOml blood) 
and one estimation of the serum blank made for each patient.
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Chapter B7 The effect of - macroglpbuXin hound trypaln on 
ohblècystokinint and laoàification of this action 
by Trasylol, leupeptin and an&ipain# -
B7.1 Introduction
, With the observation (section B6,6) that Trasylol can, in soia^  
circumstances, have a dràraatïc effect on the result obtained for the 
amount of cholecystokinin bioactivitÿ in a'given sample, it was of 
interest tp discover what effect, if ahÿ^ trypsih bound to et» - . 
taacroglobulin had on cholecystokinin activity, and, also to liote \
the effect,of inhibitors’, on'this, effect.' ■ '
Since trypsin splits the CÛ-MÏ peptide bond on the acid side -
of basic amino acids any action of trypsin bn cholecystokinin •' 
would'show as an increase lu bioactiyity, due to the,release of ij
the dodeca and octa peptides at the active C~terminal end'of tiic 
molecule (for structure see section A3.I). In fact, since the arginine  ^ ;i
bond that would release the octapeptide is surrounded by aspartic acid '
residues, it would be more likely that the active fragment.released '/-J
by the enzymic action of bC,.- tnacroglobulin bound trypsin would be the j
dbdeca-peptide, which is 10-15 times as 'activé as the full molecule j
on a weight basis (Ondetti et al>, 1970).: Cleavage at the third arginine 1 I
residue would have no effect in subsequent,bioactivity. ; I
B7.2 Method . . ' ; .
Trypsin bound to - macrogiobul in was a gift from 
the American Red Gross Blood Research Laboratory,; Bethesda, Maryland, 
U.S.A. A small: amount (365ng) of cholecystokinin-variant (39 amino acids, 
section A3.1 a gift from Professor V . Mutt) was incubated at room 
temperature (r20^C) x<?ith 5 ul oc.« - nmcroglobuliii bound trypsin 
(12 mg/ml 0^2 Macroglobulin with 300 \ug activa Trypsin/ml in 50 raM Tria- , 
hydrochloride buffer pU 7.3 containing 10 inM CàGÎ„) for 15 minutes.
At the end of this time the reaction was stopped by dilution with 
ice cold Krebs solution,
To investigate the effects Of the trypsin Inliibitora Trasylol, '■
leupeptin and antipain, aeries of reaction vessels,were prepared
each containing the same amount ,of. cholecyscokinin variant ;<3b5ng) , -
plus graded amounts of the inhibitors reduced by serial dilution
from concentrations of 2.8mg/ml for Trasylol, 200uM for leupeptin
and 150 uM for antipain to minimum concentrations of 22 ug/ml, > ‘ '
1.57'uM;and 1.17 uM respectively. A constant (5 ul) amount of -
macrpglobulin bound trypsin was added to each tube, and the/tubes
incubated at room temperature (^20^0 for 15 minutes. At the end of
this tinia the reaction was stopped as before by dilution with ice
cold Krebs solution. - .
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In addition each series was controlled with tubes 
containing only cholecystokinin-variant and “ macro­
globulin (these gave the amount of CCK bioactivity added 
to each tube), and by tubes containing cholecystokinin- 
variant and “ macroglobulin bound trypsin added as above 
(these gave the maximum amount of CCK bioactivity which 
could be expected after enzyme treatment).
All samples were then diluted to 100ml with Krebs 
solution and their cholecystokinin bioactivity estimated 
with the final automatic system (section B3.4).
B7.3 Results,
The cholecystokinin-variant treated with - macro­
globulin bound trypsin showed a 4,5 fold increase in bio­
activity over the control sample which did not contain the 
enzyme. The effects of the three inhibitors Trasylol, 
leupeptin and antipain are sho^m in Figs, B7.1, B7.2, B7,3 
and AP7, From these it can be clearly seen that while 
leupeptin and antipain considerably reduced the enzyme 
effect of - macroglobulin bound trypsin upon the cholecy­
stokinin-variant, Trasylol had little or no effect.
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B7.4 Discussion
These results demonstrate conclusively that cholecystokinin 
bioactivity can be generated in vitro by enzymic splitting of 
the whole molecule to fragments that are more active. If it 
were certain that the main peptidase in serum was trypsin it 
might be more relevant to take blood samples into leupeptin or 
antipain, considering the relative ineffectiveness of Trasylol.
However, since in practice a number of peptidases will 
be present in serum, Trasylol as a more general inhibitor, is 
still probably the material of choice, despite the fact that 
these experiments, which were performed since those described 
in chapter B6, suggest that Trasylol may not be doing its job 
as efficiently as it might at the concentration used.
While use of a higher concentration of Trasylol (section 
B6.7) has shown Trasylol to be an effective inhibitor of 
proteinase activity, routine use of these higher concentrations 
would introduce unacceptable dilution problems, correction for 
which, due to the varying amount of serum produced by each 
individual, would be virtually impossible.
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CSiapter Bo8 The effect of drugs, and other peptide hormones,
on the response of the isolated rabbit gall^ -bladder 
to cholecystokinin - containing solutionso 
B 8 a 1 Introduction
Any analytical system must necessarily be sufficiently 
specific for the substance being analysed, to permit quantitative 
estimates of the amount of the substance in test solutions to 
be made with confidence» It was therefore Important to eliminate 
the possibility of interference with the system by other 
substances. This would be a fairly easy procedure for assay 
systems relying on chemical or physical changes in the solutions. 
33.10 more complex bioassay system must be tested in a similar 
manner but much more care is needed in the interpretation of 
the results.
Hie following experiments set out to ensure ; (1) that 
choleoystokinin acts directly on the gall-bladder and that its 
action was not: mediated nor modified by associated nervous 
pathways. (2) That other peptide hormones, in particular 
secretin, motilin, somatostatin, pancreatic polypeptide, 
glucagon or pentagastrin, did not influence the effect of 
cholecystokinin on the gall-bladder when they were present in 
normal physiological amounts.
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B8é2 The effect of neurotransmitter blocking drugs
The effects of the anticholinergic drug atropine, the 
p-blocker propranolol (Inderal), the oC-blocker phentolamine 
mesylate (Rogifcine) and the anaesthetic Lignocaine, on the 
response of the isolated rabbit gall-bladder to standard 
solutions of cholecystokinin were studied using the final 
automatic equipment (section 3.4).
The gall-bladder strips were calibrated with solutions 
containing 0.5, 1, 2, 3, 4 and 5mIDU/ml of cholecystokinin 
(as Boots Pancreozymin)» This calibration was then repeated 
but with all the solutions containing Sug/ral of one of the 
drugs. Calibrations continued alternating between the 
cholecystokinin control and the same solutions containing 
5ug/ml of one of the drugs. The height of the peaks obtained 
in response to these solutions was measured and the dose-rasponae 
curves constructed,
B8.3 The effect of other peptide hormones
These experiments were performed in an identical 
manner to those described in section B8.2 for the blocking 
drugs. After priming the gall-bladder strips with two 
diluted serum samples dose-response curves were constructed 
with standard solutions of cholecystokinin (as Boots Pancreozymin) 
as before. The calibration was then repeated with each
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Fig B8.1 Dose-response curves for rabbit gall-bladder to 
graded doses of cholecystokinin alone and in the presence of the 
drugs atropine or propranolol.
□ C C K s  
▼ Rogitine  
# LIgnocain
8
0  2 4  6  8  1 0  1 2  1 4  1 6  1 8
log (dose x IO ) m l.D .U /m l Pancreozymin
Fig B8,1A Dose-response curves for rabbit gall-bladder to 
graded doses of cholecystokinin alone arid in the presence of 
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solution containing a constant amount of the peptide homone 
under test; secretin lOOrali/ml (as either Boots or Karolinska 
preparation), motiliii 20pg/ml, pentagastrin lOOpg/ml, pancreatic 
polypeptide 80pg/ml, somatostatin 4ng/ml and glucagon 200ng/ml. 
The amount of hormone used was dictated in part by the amount 
of each hormone available (e.g, total mo tilin available was 
20ng) but amounts ware also chosen to correlate witli known 
physiological levels. In addition to the calibration 
solutions one sample containing only the test hormone at the 
concentration selected was also presented to the gall-bladders• 
In a similar manner the dasulphated C-terminal 
octapeptide of cholecystokinin was applied to the gall­
bladder in graded amounts up to 1200pg/ml and also at a 
constant concentration of 800pg/mX in conjunction with 
graded doses of cholecystokinin,
#8,4 Results
There was no significant difference between the 
response of the gall-bladders to ciiolecystokinin alone and 
the response to the same dose in the presence of atropine, 
propranolol, lignocaine or phentolamine mesylate (Fig.B8.1).
This confirms the accepted belief that cholecystokinin acts 
directly on the gall-bladder tissue and not through any
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Intermediate pathway,
Interaction with other peptide hormonea however 
manifested itself as either; no effect, slight inhibition 
(except for the Boots preparation of secretin Fig. B8«S) 
or slight enhancement (Figs. B8*2, B8i3, B8.4-) . These effects 
are summarised in Table B8.1.
The desulphated (/"terminal octapeptide of cholecystokinin 
had no significant activity on its own^  even at a concentration 
of 1200pg/ml, while whan applied to the gall-bladder in 
conjunction with cholecystokinin it exerted a slight inhibitory 
effect (sea Table B8.2),
B8»5 Discussion
These results confirm that the action of cholecystokinin 
is directly on the gall-bladder tissue and is not mediated 
through any nervous pathway. The interactions with the other 
peptide hormones are interesting but it appears that the 
inhibitory effects just about match the enhancing effects 
creating an overall balance of no effect. Thus these inter­
actions, would not therefore appear to alter significantly 
the gall-bladder response to a dose of cholecystokinin when 
all the hormones are present together.
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Table B8.2
Response of the isolated rabbit gall-bladder to the 
desulphated C-terminal octapeptide of cholecystokinin and 
to graded doses of cholecystokinin in the presence or 
absence of the desulphated octapeptide.
dose ofuu Ul.
cholecystokinin dose of desulphated gall-bladder response
in mlDU/ml octapeptide in pg/ml height of peak in cm.
400
800
1200
0.4
0.6
0.5
5
3
2
1
0.5
5
3
2.
1
0.5
800
800
800
800
800
13.0 
9.8
6.1
3.7 
2.1
12.0
8.7
5.7 
3.1 
1.4
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The experiments with the desulphated C-terminal octapeptide 
of cholecystokinin demonstrate the total loss of activity 
that occurs with the.removal of the tyrosine sulphate grouping,
Xt was not surprising therefore to find that this desulphated 
molecule had some inhibitory effect on the normal molecule. 
Although the sulphate grouping is essential for biological 
activity it is unlikely that this grouping alone determines 
, binding at the receptor sites. The desulphated molecule will 
almost certainly bind to the receptor sites and block them, since 
this binding.must be reversahia,inhibition of the natural molecule 
by the desulphated molecule is most likely to be of a'competitive 
nature.
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Chapter B9 Identification of different molecular forms of 
cholecystokinin in 'human serum 
39.1 Introduction
This work began from the observation that vary few 
radio-immmioassays for cholecystokinin had been established 
through the world 3 and those that were established were 
making few appearances in the literature. The difficulties 
were not confined to problems encountered in labelling the 
pure cholecystokinin (sea Section C); severe, difficulties 
also seemed to be encountered in obtaining antibodies to 
c h o l e c y Stokininp and it could take up to 18 months of 
Immunisation before antibodies could be detected in the 
serum of even one of a batch of test animals (Young, Lazarus 
and Chisholm, 1969). Even then there was no guarantee that 
these antibodies raised to porcine cholecystokinin would 
react with human cholecystokinin, and suggestions were made 
that a major structural difference could exist between the 
porcine and human cholecystokinin (Go, Ryan and Summershill, 1971).
To investigate this possibility it was decided to try 
to isolate sufficient cholecystokinin from human serum to 
enable an amino acid analysis to be performed. Early 
experiments in this direction were not encouraging; it was
- 79
impossible to locate cholecystokinin acitivlty in fractions of 
column effluent; and it also became clear that many litres of 
serum would be. required to obtain sufficient cholecystokinin for 
an amino acid analysis to take place. Therefore after the 
early experiments the research was directed at identifying 
cholecystokinin activity in column effluents and the idea of 
obtaining the amino acid sequence was temporarily shelved.
B9.2 First Experiment
A 1.5 K 100 cm column (Pharmacia Fine Chemicals Ltd.
K26 column) was packed with Sephadex 050 (fine) and equilibrated
•saturated
with Krebs solution/with Benzene,
50ml fresh serum was applied to the column which was 
then eluted with Krebs solution saturated with benzene. The 
column effluent was collected in 15ml fractions.
Each fraction was diluted to 100ml and examined for 
cholecystokinin activity with the final automatic system.
No detectable cholecystokinin was found in any fraction# 
The experiment was repeated, but this time the fractions 
were pooled in sixes (1-6, 7-12 etc) forming samples of 100ml 
for testing for cholecystokinin activity as before. Again no 
cholecystokinin activity was found in any of the samples from 
pooled fraction.
FP20
Il . ni
C O tO «O O M 4c
To ricordér
& atnplifrtf^ Tranajoqer
Main contRX Condwctivily 
TImaf Defector^ ^
Saphadex
iScm
To W à s le ^
Krebs *o*n
Fîg B9.1 M odified opporatus for monitoring column effluen t for cholecystokinin  
b io a c tiv ity .
80 "•
B9o3 Second Experitnont
The elufcion for the first: experiment had been carried out 
at room:, temperature and the fractions stored at room temperature 
until tested. It was felt that this was at least part of the 
reason for failure to detect cholecystokinin activity in the 
column effluert. It would have been preferable to feed the 
column effluent directly onto the assay system but a previous 
experiment using a column of this size (1,5 % 100cm) bad 
failed. The scale of the experiment was therefore reduced,
B9.3*l Apparatus and Column Calibration
For this experiment the automatic equipment was 
disconnected from the bioasssy apparatus and the effluent 
from a 1 x 15cm column of Sephadex G50 was fed directly 
into the main stream of Krebs solution (Fig. 9,1), A short 
coil was added to ensure adequate mixing before the stream 
was split to supply the two gall-bladders. The column 
was eluted with Krebs solution, and the final dilution of 
the column affluent when the stream was split was about 10;1,
Blue dextran, which was totally excluded from the 
G50 gelp. and 250 mIDU (mill! Ivy Dog Units) of cholecyotokinin 
were used to calibrate the column, these marked the position 
of elution of die void volume and molecules of molecular weight
FpSl
Elution pattern of serum from Sephadex 650 1 x 15 cm column, 
effluen t direc t to CCK bioassay system. i,-
Void Vol ÇG K+Obtapeptide
sÛC
6
5
4
3
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0
Time(fnins)
Fig B 9 .2  ‘ Elution pattern o f cholecystokinin a c tiv ity  in serum from a 
Sephadex G 50  1 x 15cm column w ith the effluen t fed d irec tly  to the 
bioassay system,
•; :•
■I ; ;
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around 4,000 - that of cholecystokinin, - respectively. The 
position of elution of the blue dextran was observed visually, 
that of cholecystokinin was marked by the response of the gall­
bladders.
B9.3.2 Behaviour of cholecystokinin octapeptide on the column
Bioactivity from cholecystokinin applied to the column as 
G.I.H. Karalinska Cholecystokinin, Boots Pancreozymin or the 
synthetic C-terminal octapeptide of cholecystokinin all eluted 
from the column in the same position. This small column was 
therefore unable to separate the small octapeptide from the 
full molecule,
B9.3.3 Separation of Serum
Two millilitres of serum were applied to the 1 x 15 cm 
column and the elution continued with Krebs solution. The 
traces from the gall-bladders were examined after 15 minutes - 
the time calibrated for complete elution of the column.
Two areas of cholecystokinin bioactivity were observed 
(fig, B9.2), one was in the expected position for cholecystokinin 
the other appeared with the void volume.
A second serum sample gave the same result, and elution 
on a longer 1 x 60cm column simply enhanced the separation.
FP?J-
Big CholMystokinin
I
Fasting
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Fig B 9.4 Proportion o f 'b ig ' end normal sized cholecystokinin- 
like ac tiv ity  eluted from a Sephadex G 50 1 x 15cm column^ 
showing differences in the serum content of the two 
'cholecystokinins' when fasting and after ingestion of a m ea l.
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#9*3*4 Effect of feeding
Volunteers were asked to undertake an overnight fast 
and then exchange some blood for our standard fatty breakfast 
(Fig, Blood samples were taken fasting, and 15 and
30 minutes after completion of the meal. The blood was 
dispensed into tubes containing 10,000 K.IoU. Trasylol per 
10ml blood, and after clotting the serum iwas collected,
2ml samples of each serum were then applied to the 
1 % 15cm column, and tho areas ™ since solutions of constant 
strength were not being dealt with - of the peaks determined.
Further serum samples containing added cholecystokiniii were 
also applied to the column.
B9.3.5 Effect of Trypsin~ i  r -  r n r t n r T - ^ n i f  i i i r n r ~ v r i r T n r — p i i u j m  t i m j  a r f i n
Samples of serum were digested with Trypsin for 30 
minutes at 37°C, these digests wore applied to the longer 
1 % GO cm column of Sephadex G50 eluted with Krebs solution 
directly on to the bioassay system as before.
B9 9 4 Results and Discussion
Fig, B9s4 shows the proportions of the two choleeystokinins 
found in the serum of 4 normal healthy volunteers, the height of 
the columns indicating the peak areas (in arbitrary units) found 
for *bi$ cüolacystokiîiin* (above the line) (that area of choleeystokinin
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Elution pattern of CCK-active peptides from 1 x 50 cm column 
Sephadex G50.
Sample: 2 ml human serum treated 30 min at 37°C with Trypsin.
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Fig 89 .5 EluMon pattern of choleeystokinin •  like activity^ in serum treated 
with trypsin^ from a Sephadex G 50 1 x 50cm column.
bioactivity eluted with the void volume of the column) 
and normal size cholecystolciriino (below the line) in the 
fastingtj 15 and 30 minutes poot-meal serum samples.
It appeared that in response to feeding there was 
a reduction in the amount of 'big choleeystokinin' and, 
in moat cases, an increase in the amounts of the normal 
sized cholecyatokinins. At this time it was impossible 
to aay whether this was due to the release of neiT normal 
cliolecystokinin with a consequent reduction in die amount 
of 'big choleeystokinin', or if the 'big cholecystokin' 
was a means of storage or a precursor.
Boots Pancreozymin, the Karolinska Choleeystokinin 
and the synthetic C-terminal octapeptide do not alter their 
position of elution when added to serum, it was therefore 
unlikely that 'big choleeystokinin' is simply normal 
choleeystokinin attached to a ^carrier since at least a 
small increase in 'big choleeystokinin' would be expected 
after the addition of exogenous choleeystokinin,
four areas lig. 59,5 of cholecystokinin-like activity 
were eluted from the column to which tryptic digests of 
serum had been applied. Two in the positions already 
described with the other two between them.
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Since it was totally excluded from the G50 gel 'big 
choleeystokinin' must have a molecular weiglit in excess of 
30,000. The experiment with trypsin encouraged the bolief 
that *hig choleeystokinin' was a protein in its own right 
with a molecular weight in excess of 30*000 although the 
possibilities of a polymer or aggregate cannot he ruled 
out at this stage.
Attempts were made to achieve a separation on a 1 %
13era column of Sephadex GlOO, but the flow rate through this 
column was too slow, this resulted in the final dilution of 
the column effluent being too great for any cholecystokinetic 
effects to be seen in terms of a contraction of the gall* 
bladder. This particular problem may be overcome by collecting 
fractions and this possibility is being examined.
Chapter BIO Biological Measurement of Cholecyotokinin xn Clinical 
Practice 
BIO.1 Introduction
Much of the physiolog)'' of choleeystokinin is known and 
documented (see Chapter A4); it is known that the main source 
of choleeystokinin is the upper small intestine, in particular 
the duodenum, the main target organs are the gall*bladder and 
tho pancreas, and it is firmly established that amongst the 
stimuli for choleeystokinin release are the presence of acid 
or fat in the duodenum,
Therefore, since these things were known, it was of 
interest;.to look at patients whose raetabolisu might be 
altered by disease of, or a surgical operation on, one of 
the target organs, or a portion of the gut manufacturing 
choleeystokinin, and to compare these patients with other 
normal controls,
510,2 Protocol for Study
Patients were selected and grouped orly according to 
the operation to be performed, Early patients were given 
a full work up * overnight fast, then blood samples taken 
while fasting and then 10 min, 20 min, 30 min, 60 min and 
120 min, following a standard fatty breakfast consisting of;
1 fried egg, 2 rashers of fried bacon, 2 slices of bread, 
butter and marmalade, and 1 or 2 cups of tea or coffee with 
sugar to taste (see Fig* Bl*4), This procedure was performed
preoporative1.y and repeated pootoperatively, or pootoperafclvely 
ouly (and compared with a control series) at least one month 
after the operation. In later patients only fasting samples 
wore taken at the two specified times,
BlOgS Controls
To establish the normal range for scrum choleeystokinin 
volunteers assumed to be normal* healthy and witii no history of 
gastrointestinal disease were asked to undertake an overnight 
fast, A single fasting blood sample, was taken from some of the 
volunteers* others were given a full 'work up' with blood 
samples also being taken 10 min, 20 min, 30 min, 60 min and 
120 min, following a standard fatty breakfast. In a second 
series fasting blood samples were taken from a different set 
of volunteers and the blood dispensed into tubes containing 
10*000 KIU Trasylol per 10ml of blood.
B10 o 3.2 Re su. 11@
Of the two series of controls obtained, only the first 
series which did not use Trasylol was applicable to the trials 
described below. The series using Trasylol may be taken as 
the normal fasting control value expected in the trial detailed 
in chapter Bll,
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Tue mean fasting value, of circulating choleeystokinin 
for normal controls in the first series was D1 27mIDU/ml 
Bcrum^ obtained from 19 volunteers consisting of 10 moles 
and 9 females (range 46 * 135mlDU/ml).
In the second series the mean fasting value was found 
to be 28 16mIDU/ml scrum from a scries of 13 volunteers 
cozisisting of 7 males and 6 females (range 10 - 75mIDU/ml).
There was no significant difference between the values 
obtained for male and female volunteers in either of the two 
groupse
BIO.4 Operations By-passing the PuodenuBi 
BlQ,4ol The short loop Polya Partial gastrectomy 
B10,4.1,l Operation and method
This operation (see Fig. 510,1) removes the antrum of 
the stomach then lifts tlie jejunum and anastomoses this near 
its junction with the duodenum to the remains of the stomach.
This leaves a loop of duodenum into which food will not pass 
except by reflux. Patients in this group would therefore 
be expected to show only a small response to food.
Five patients were studied postoperatively as described. 
BIO.4.1.2 Short loop Polya partial gastrectomy; results
The five patients in this group had fasting choleeystokinin 
levels below that established as normal and all had only small
FP29
DUODENUM
JEJUNUM
Fig B lO .l D e ta il o f the surgical procedure for short loop 
Polya partial gastrectomy.
DUODENUM
DUODENUM 
JEJUNUM-
Fig B IO .2 D e ta il of surgical 
procedure for Billroth 1 
gastrectomy.
Fig B IO .3 D e ta il of surgical 
procedure for Roux -  éri -  Y  
gastrectomy.
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incroaseeg (one case no increase) in serum choleeystokinin 
following a meal (Table #10*1)
#10*4. 2 The Billroth I Gastrectomy 
#10,4*2,1 Operation and method
This operation (see Fi#» BIO.2) removes the some 
anatomical parts as the short loop polya, hut the gastric 
remnant io connected differently* In this case the antrum 
and pyloric sphincter are removed from the stomach leaving 
the fundus and at least part of the body anastomosed to the 
duodenum. Although the source of gastrin has been removed, 
and acid secreted from the fundus of the stomach has no real 
barrier to its passage into the duodenum, it would be 
expected that these patients should have a more normal 
response to food than after a polya gastrectomy. A total 
of seven patients were studied postoperatively as described. 
Bld*4.2,2 Billroth I Gastrectomy; results
Mixed results were obtained from the seven patients 
studied in this group (Table Blv.2), two patients (1 and 2) 
had serum choleeystokinin levels above the normal range 
(see section blO,3,2), three were at the upper limit of 
normal (3, 4 and G) and one displayed no activity at all 
in the fasting state but showed a steady rise in activity 
to 48mIDU GGK/ml in the first hour following a meal but
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ali showed a aignificaiit rise in eholacystokinin activity, 
ïiie imam, rise in csiiolecystokinin activity following a meal 
was 41mluU/ml serum. The variation between patients may 
reflects different rates of gastric emptying* but Uie rise 
in activity contrasts with the polya and is to be expected 
since in uhis case the duodenum is stimulated.
Blu.4.3 The, konx en Y Gastrectomy 
B1U,4,3,1 Operation and method
This operation (see Fig, hlu,3) again removes the 
antrum*most of the body of^the stomach and pyloric sphincter 
from the patient, but the Kieèliocl of reconnection follows 
another pattern; the patient is left with the fundus of the 
stomach anastomosed to the jejunum and with the duodenum, 
through which bile and pancreatic juice may enter the 
jejunum, as a closed side piece anastomosed end to side 
to the jejunum*
The food of patients who have had this operation, 
and any stomach acid will therefore pass directly to the 
jejunum and very little will enter the duodenum which is 
the main source of choleeystokinin and the point of stimulus 
for its release. These patients would therefore be expected 
to have low levels of choleeystokinin circulating postoperatively
- 90 -
nnd 3 small, delayed response to food.
Three patients who had had this operation were 
studied postoperatively.
BIO.4,1»? The Roux - en - Y Gastrectomy; results.
The three patients studied in this group had fasting 
choleeystokinin levels at the upper end of the normal range. 
They all showed only a slight and very delayed increase in 
serum choleeystokinin activity at one hour or later following 
the fatty breakfast (Table BIO.3),
E10.5 Operation Affecting Stimulation 
BI^.5.1 Highly Selective Vagotomy 
BIO.5 ,1.1 Operation and method
This relatively new operation is now commonly performed 
to treat n duodenal ulcer. The operation involves severing 
the vagus nerve at specific points so that the acid secreting 
cells (parietal) of the fundus and body of the stomach are 
denervated while the nerve supply to the antrum and pyloric 
sphincter remains intact.
Both fasting and stimulated gastric acid output is 
reduced, but gastric emptying is nearly norijal.
Nine patients were studied preoperativcly ana five of 
these were re-examined after their operation.
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BIO.5.1.2 Highly Selective Vagotomy; results.
The complete study was performed on five patients in this 
group; preoperative fasting serum choleeystokinin levels were 
all at or above the upper limit of normal and the response to 
the meal was in some cases excessive (Table BIO.4)
Following the operation fasting serum choleeystokinin 
levels had dropped to well within the normal range, and the 
response to the meal was also more normal. This difference 
in fasting choleeystokinin levels was significantly different 
(P<0,01, paired t-test) and this is exactly as would be 
expected from the performance of this operation.
BIO.6 Target Organ Effects
BIO.6.1 The Cholecystectomy Operation
BIO.6.1.1 Operation and method
This operation simply removes the diseased or stone 
filled gall-bladder. It was of particular interest to study 
patients undergoing this operation since the removal of a 
target organ was most likely to have an effect on serum 
choleeystokinin levels. In particular an Increase in 
activity of considerable size could be expected to be 
generated if the observations and theory of Carol!, Plessier 
and Plessier (1960), that there is an anti-choleeystokinin 
substance which probably originates in the neck of the
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gall-bladder, are correct. 17 patients took part in this 
experiment and were treated as described in section BIO,2,
BIO.6.1.2 Cholecystectomy; results
In the majority of cases (16 out of 17) an increase in 
the fasting level of serum choleeystokinin was observed 
following the operation, the one patient showing a postoperative 
drop in serum choleeystokinin had choleeystokinin levels 
within the normal range (section BIO.3.2),
The results of this experiment are shown in Bigs.
BIO,4 and BIO.5 and also Table BIO.5, a statistically 
significant difference was found (P<0.001) for the pre and 
post operative observations using Students t-test for paired 
data.,
BIO.6.2 Chronic Pancreatitis
It would be expected that disease of the pancreas 
would also have some effect on circulating choleeystokinin 
levels, and indeed Harvey, Rey et al* (1976) have de^nstrated 
raised serum levels of choleeystokinin in patients with 
pancreatic disorders associated with deficiency of the 
pancreatic exocrine system, and they have suggested that 
this could be of some use in diagnosis.
Table BIO,5
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Cholecystectomy Results 
Patient
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
ralDU/mi serum 
pre-op post-op
83
75
90
39
18
42 
96 
45 
24
105
43 
28 
30 
33 
95
102
90
115
121
79
48
118
69
75
83
197
135
41
51
146
150
237
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’Insufficient patients with proven chroiiic pancreatitis 
without other complications were available for our study; \ 
and it has not yet been possible to confirm or refute the . 
findings of liarvey and his corworkefs, but. Planche, Chau-^ Huu, .
Lai and Series (1977) could not demonstrate a change in 
circulating choleeystokinin in chronic alcoholic dogs. . .
BIO.7 Discussion
In these trials it has been demonstrated that following, 
a cholecystectomy operation the fastiiig level of serum 
cholecyiitokinin rises significantly, conversely following 
a highly selective vagotomy, operation fasting serum cholecyjidkinin 
levels fall significantly. Results from gastric operations 
diverting the food supply to other parts of the small bowel were 
as expected ffdm the anatomical rearrangements tending to ..show 
a diminished response but with serum choleeystokinin levels 
about normal.
, We ,can speculate that this rise in serum choleeystokinin 
following cholecystectomy is due to the removal of the . 
iiiiiibitor postulated by Carol! et ai* (I960) but an alteration 
to bile salt metabolism could also contribute, while the fall 
following highly selective vagotomy, is clearly a consequence 
of reduced acid output by the stomach.
** 94 —
These results are interesting and should be persued 
further, the results demonstrate the extremely cosqjlex 
nature of the hormonal control of the gastrointestinal tract, 
but are very much as expected and demonstrate that It is 
possible to detect tlie predicted physiological changes 
despite the minute quantities of hormone involved. However 
one of the major problems with this study is the rate of 
gastric emptying, this can neither be controlled nor predicted 
and as a result a late peak from a slow eu^tier could be 
missed, although it is felt that the protocol used gave the 
best chance of seeing a choleeystokinin peak should one 
occur*
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Chapter Bll; Choleeystokinin and Obesity
Bll.l Introduction
This experiment arose from the observations of Young,
Gibbs et al (1974), that injections of choleeystokinin to 
rats with gastric fistulae that are sham feeding caused the 
rats to exhibit all the signs of satiety. It was therefore 
of interest to study obese patients and look for any significant 
differences in their fasting serum choleeystokinin levels 
or the pattern of choleeystokinin release following a stimulus.
Our hypothesis was that hyperphagic obese patients ate 
continuously and to excess because there was a failure in 
choleeystokinin output and therefore no satiety signal to 
tell them to stop eating.
Bll.2 Method
Patients were selected and divided into three equal 
groups, these were: (A)& Normal lean, people with no known gastrointestinal 
disorders and no previous history of such disorders and of normal 
weight, (B)* Normal obese; people who were overweight but had a 
normal appetite and again no knowngastrointestinal disorders or 
history of such disorders. (C)* Hyperphagic obese; people over­
weight and with an abnormal appetite, that is compulsive eaters, 
again no known history of gastrointestinal disease.
* For definition of A,B and C see Appendix E p, 159,
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: All thase patieiits. were treated in the same manner j
following an overnight fast' (notiling to eat or drink or smoke , 
from midnight to thé .time of thé .test ~ aroxmd 9 â.m.) 10ml 
, : blood smaples were taken five minutes before and immediately
,• before (aero time) they were given a liquid meal of approximately 
.450ml *Build “Up* (Carnation).'. Further blood samples were taken 
5 min, 10 min, 15 min, 30, niin, 45 raiii and 60 min* following, 
consumption of the liquid .meal. - . ■ -r
. :The blood was dispensed into tubes containing 10,000 
K.I.U, irasyloi per. 10 ml blood. Aftef : clotting the serum 
;' \was collected and stored frozen until required. • ;
L “ Gholecystokinln bloàctivity in each sample was measured 
using the.final'automatic system (section B3.4) and one '
estimation of * serum blank* (section B6 *9) was made for 
each patient. The analysis was performed *blind*$ th&t;is 
; . without, knowledge .of the group to. which each patient belonged.
BII.3. -^rHesùlts - ‘
Individual results are recorded in table Bll.l. There'was no 
significant differenca between.the groups in serum cliolCcystokiniu 
content in either of thé two fasting samples,' the peak values, 
the timing-of the, Gholecys'tokihin peak following the meal nor 
in the'actual .rise inxiserum choiGcystokiniii (P-F/mn) j and in 
no between group,Comparisons with an unpaired t-test did the.
X value obtained for t correspond to a P value lower than 0;2, i.e 
P 0*2 on all comparisons.
B11.4; Discussion
Each group of patients exhibited, the x-yhoXe range of 
values for■serum cholecystokinin from the lower end of nonaal 
through the upper limit and beyond to that which would be 
classed abnormal. All.patients showed a reasonable response 
to the meal as raised serum cholecystokinins ” generally 
'mthih 30 fflim and of significant order.
Shoiiih chd lacy s t okinin be‘a satiety signal in human beings 
(although this has yet to be demonstrated) (Goetz and Sturdevant, 
1975) failure of hormone production iii hyperphagic obese patients 
clearly does not occur.' If cholecystokinin. is to be’ .implicated. 
in this connection it must bo as a. failure of the receptor site to 
respond to cholecystokinin and hot the failure of the body to 
produce and release cholecystokinin.
SECTION G
RADIOIMMONOASSAY
Labelled
Antigen
Specific
Antibody
Labelled, Antigen 
Antibody Complex
Ag*
(A)
Ab
(B)
Ag* - Ab 
(C)
Unlabelled 
Ag Antigen as unknown 
Or standard
/I
V 
(D)
Ag-AbUnlabelled Antigen- 
Antibody Complex
Fig Cl.l
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Chapter Cl Introduction 
Cl.l Background
RadioioMunoassay is a much more recent arrival in the 
field of methods for measuring biological molecules - in 
particular human serum or plasma - than bioassay. The 
technique appeared as a spin-off from Mirsky's (1952) 
hypothesis that maturity-onset diabetes might be due to rapid 
degradation of insulin rather than a secretory deficiency.
This led directly to work by Berson, Yalow, Bawnan, Rothschild 
and Newerly (1956) and a demonstration of an insulin-binding 
globulin in the circulation of insulin-treated subjects,
(Yalow and Berson, 1959)• There are many radioimmunoassays 
for other gastrointestinal hormones some of which are 
commercially available, cholecystokinin is a most notable 
exception,and has rarely yielded to radioimmunoassay (see 
Chapter A3.2).
The sis^licity of the reaction involved in a radioimmuno­
assay is summarised below in Fig. Cl.l.
These are competing reactions and the amount of labelled 
antigen that will be bound to the specific antibody depends 
upon the amount of unlabelled antigen with which it is competing 
for the antibody binding sites.
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The antigen-antibody coi^lex may then, depending on 
the valencies of the two contributing components (antigen 
and antibody),4ormaggregatea, with the complexes eventually 
foradag a matrix of sufficient size to precipitate spon­
taneously* Generally the antigen is multivalent, the valency 
of antibody being limited to 2 (Eisen and Karush, 1949).
This permits the formation of three-dimensional cortpXexes 
with resultant precipitation. However in certain special 
cases the antigen may be so small as to be only taono-or 
di-vaient, in these eases it is unlikely that the antigen- 
antibody complexes would form aggregates of sufficient size 
to precipitate spontaneously.
Cholecystokinin la one antigen which by its size 
would not be expected to be more than di-valent and is 
probab lÿ mono-valent. Since separation of A from G (Fig. 
Cl.l) is required for a working radioimmunoassay further 
treatment of the reacting solutions is necessary. Three 
main methods of achieving this separation are available 
(Harvey, Dowsett, Hartog and Read 1974).
(a) Charcoal Separation
Charcoal will absorb free lalselled antigen (A) but 
hot antibody-bound labelled antigen (c). Separation of
— 100—
free and bound labelled antigen can therefore be achieved 
by mixing a little dextran-coated charcoal (chapter B6.5) 
with the incubation mixture, removing the charcoal by 
centrifugation and testing both the charcoal and the super­
natant for radioactivity.
(b) Ion exchange resin
A similar effect may be obtained using Amberlite 
CG-40Q ion-exchange resin, this absorbs the free but not 
the antibody bound labelled antigen. The resin is removed 
by centrifugation and both resin and supernatant arc counted 
for radioactivity as before,
■(c) : Use of a second antibody
In this case a second antibody directed against the gamiiia-globulin of 
the species used to raise antibodies.against the antigen under test 
is added to the incubation mixture. This may be done either before 
or after addition of thé labelled antigen and the test sera or standards.
In practice methods (a) and (b) have been found unsuitable for 
cholecystokinin investigations (Harvey et al 1974) and method
(c) was adopted for this study,
01.2 Principle of the working assay
To establish a fadioimmunoassay for a given compound 
antibodies against that compound must first be generated by
F P lo i
100 -§5 Antiserum MS6 double antibody mettiod maximum sensitivity2B 90"o
80-
a
70-a
go
S 60-V
oI 50-^ 104 862
Picograms CCK-PZ added to incubation mixture
Fig C l .2  Standard curve using a rabbit antiserum with a
131double antibody separation and I -  CCK of high 
specific a c tiv ity  ( from Harvey et o l .  ^ 1974 ) .
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iiijectiag the confound into an miimal, either in pure form 
or coupled to a larger modecule e*g* Bovine Serum Albumin 
to enhance its antigenicity^ and time allowed for the Immune 
response to occur.
Blood is taken from the, animal, the serum collected 
and diluted to a concentration suitable for use. To portions 
of this antiserum are then added a specific amount of the test 
compound, to which a radioactive tracer has been attached, and 
graded amounts of the natural (or cold) compound.
After separation of the free radiolabelled compound 
the amount of radioactivity bound to antibody in each case is 
determined. A calibration line for the amount of radioactivity 
bound in the presence of graded amounts of the cold compound 
is thus obtained.
The amount of the test compound in any unknown test 
sample can now foe determined by reading the amount of cold 
compound that corresponds to the amount of radioactivity 
bound by the test samples (see fig# Cl,2 for an example).
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Chapter C2 Immunisation Procedure 
C2,l Selection of animais
Initial procedures were carried out using young New 
Zealand Milite Rabbits, These were, eventually replaced with 
rabbitasof the Old English strain. One series of inmunlsationa 
was also carried out late in the programme using eight GEY 
rats and 6 Dunkon and Hartley guinea pigs,
C2,2 Treatment of Animals 
C2,2,l Material Injected
At each injection the animals received either 25 Ivy 
dog units of cholecystokinin (Pancreozyioin, Boots Pure Drug 
Co,) or 75 Ivy Dog Unite of cholecystokinin (liarolinaka Institute 
for Gastrointestinal Hormone Research) dissolved 0,5 ml Krebs 
solution and emulsified with 0.5ml Freund's complete adjuvant 
(Difco). On some occasions the cholecystokinin was coupled to
Britishpolyvinylpyrrolidone (M,W, 400Ç000/Drug Houses Ltd) to increase 
the immunogenticity. The coupling was performed according to 
the method of Assan, Rosselin, Drouet, Dolais and Tchobroutsky 
(1965 ); the Cholecystokinin was dissolved in 0,75ml distilled 
water, mixed with 0,75ml of a 25% solution of polyvinylpyrrolidone 
(P.V.P.) and after incubation for one hour at this viscous
mixture was injected into the animals.
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02.2.2 Ifetthod of Injection 
02*2.2 .1 Rabbits
These animals received (one of the above preparations 
at each injection;) after the first priming challenge the 
animals ware given a boosting injection 10-14 days later and 
thereafter further boosting injections at monthly intervals. 
Initially the animals were injected intrademally at multiple 
sites ^ cleared of fur along the back, approximately 0 ,2al 
being Injected at each site, later animals received 0,25ml 
under each scapula and 0,25ml intramuscularly to both hind 
legs.
02.2.2.2 Guinea Pigs
Each guinea pig was injected subcutaneously with Boots or 
Karoliiiska Cholecystokinin not coupled to at multiple
sites, 0.2ml being injected at each site. Following the initial 
priming injection a booster injection was given 10-14 days 
later; thereafter the animals were given booster injections 
at monthly intervals. Individual animals were recognised by 
colour code witli dye sprayed on their fur.
02.2.2.3 Rats
The whole 1ml sample of uncoupled Boots or Karolinska 
Cliolecystokinia was injected into the peritoneal cavity of
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each iat* Again, following the initial priming injection* a 
booster injection was given after 10-14 days and thereafter 
further boosting injections at monthly intervals. Individual 
animals were identified by coded ear punches.
C2.2.3 Withdrawal of blood from animals 
C2.2.3.1 Rabbits
Fourteen days after tlie fourth injection ** to try to 
catch the peak of the immune response - 10 to 25ml of blood 
was taken from each animal by ear vein puncture. When the 
animals were killed they were first anaesthetised with a 
sub-lethal injection of "Ejïpiral’*, 80 - 100ml blood was 
then extracted from each animal by cardiac puncture.
Samples of blood from unimmunised control animals were taken 
at the same time.
C2.2.3.2 Guinea Pigs
Fourteen days after the fourth injection the animals 
ware exposed to CO^ and 5 ml of blood taken by cardiac puncture 
while, the animal remained unconscious. At death the animals 
were again made unconscious with GO^ and 25ml blood taken by 
cardiac puncture.
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02*2*3*3 Rate
Fourteen days after the fourth Injection the animal# 
were anaesthetised with either ether or halothane* ApprpxliMtely
2ml of blood was taken from each animal via the orbital sinu»*
At death, up to 8ml of blood was obtained from each animal by 
cardiac puncture*
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Chapter C3 Preparation of radlolabelled cholecystokinin 
C3.1 Incorporation of 125 1 Into the cholecystoklnln molecule 
C3.1.1 Chloramine T method
Very highly purified (99% pure) cholecystokinin (a 
gift from Professor Victor Mutt, Gastrointestinal Hormone 
Research Laboratory, Karolinska Institute, Stockholm) was 
used for the labelling procedure. Tlie procedure used was 
a modification of Hunter and Greenwood's (1962) Chloratuine-T 
method, as described by Harvey el at (1974)»
1 ug cholecystokinin was dissolved in 200y/1 Sorensen&a 
phosphate buffer (see appendix for composition of buffer)^ 
0o05M, pH7,4p the glass vial that had contained the dried
cholecystokinin being used as the reaction vessel. 500 vG
125 . ,radioactive iodide as Na I (Radiochemical Centre Amershaia,
product IMS 30) and 20 ug of chloramine-T in 10 jjI of buffer 
were added and mixed. The reaction was stopped after 10-20 
seconds by the addition of 50 wg sodium metabisulphite in 
10yi/1 phosphate buffer. The reaction mixture was diluted 
with 200jjI of a solution containing lOmg/ml potassium iodide 
and was then applied to the top of 1 x 15 cm column of 
Sephadex GIO, or G15, or Biogel P.4 equilibrated with the 
same phosphate buffer. The column was eluted with the
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phosphate buffer and the effluent fed through a coil of 
microbore tubing attached to a ratemeter detector, the rate- 
meter itself was attached to an ultraviolet recorder. T\m 
peaks of radioactivity were ellited from the column, one just 
after the void volume - assumed to bo. radioactive cholecystokinin 
and the other, larger peak - assumed to be unreacted iodide - 
much later.
C3.1.2 Use of Lactoperoxldase
125Some attempts were made to attach I to cholecystokinin
using lactoperoxidase. The method used was as follows:
125 125200yvC of I (as Na I, Radlochemical Centre, Amersham,
IoM.S.30) was placed in a small plastic tube, 1 jjg of 
cholecystokinin in 400™500j j I  Veronal Buffered Saline (V.B.S* 
see appendix for composition) was added, together with 5 jjI 
Sodium iodide solution 10,6 mg/lOOtul VoB.S.), 5y/1 lactoparoxidase 
(1 mg/ml V.B.S.) and 5 jjI hydrogen peroxide (30% (100 volume) 
diluted 1:10,000)* The tube was shalcen and left to stand for 
15 minutes when 10yul of a solution containing 6 mg/ml sodium 
iodide and 0*03 mg/ml sodium aside were added to stop the 
reaction,
Since cholecystokinin passes through dialysis tubing
the bound and free iodide ware separated by applying the reaction
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mixture to the top of a 1 x 15 cm column of Sephadex GIG or 
G15 and eluting the column with Fractions were collected
and the positions of elution of radioactive peaks determined 
by passing the column effluent in front of a detector attached 
to a ratemeter.
However in a control experiment with no added cholecystokinin,
125it was found that the same amount of % was being incorporated 
into protein. It was therefore concluded that the lactoperoxidase 
was attaching the label to itself rather than cholecystokinin,
03.2 Addition of Tritium to Cholecystokinin
Lack of success with the above two methods was attributed 
to (a) steric hindrance of iodine addition by presence of the 
sulphate group on the only tyrosine residue in the cholecystokinin 
molecule. Substitution of iodine in the positions ortho to the 
sulphate group - the normal point of substitution for these 
iodinating reactions would appear to be impossible; (Fig 03.1)
(b) breakdown of the cholecystokinin molecule in the severe 
conditions associated with Chloramine-T oxidation. An alter­
native milder method of incorporating a radioactive label into 
the cholecystokinin molecule was therefore sought.
Fricjq
Fig C3.1 Sulphated tyrosine residue showing the theoretical
125problem of attaching a I atom in positions ortho to the 
sulphate group. Colour code: block = carbon; 
white = hydrogen; red = oxygen; blue = nitrogen; 
brown = sulphur; green ( not to scale ) = iodine .
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Chemical modifications of proteins was found to be well 
described by Means & Feeney (19 71) and the method of reductive 
alkylation of proteins fully described by them three years 
earlier (Means & Feeney 1968).
They described methods for the addition of several alkyl 
groups and reported that the reaction appeared to be highly 
specific for amino groups. Careful examination of acid 
hydrolysates by amino acid analysis failed to demonstrate 
the loss of any amino acids apart from those which are N- 
terminal and also lysine. Although cholecystokinin has an 
N-terminal lysine, Means & Feeney (1968) state that alkylation 
of N-termihal lysine was incomplete,
Cholecystokinin has two lysine residues (at positions 
1 and 11 - conventional count from N-terminus) and it would 
seem possible that tritiated isopropyl groups could be added to 
these positions without too great a loss of antigenic specificity.
Reductive alkylation rcholecystokinin was therefore
carried out in the following manner: 1 jjg cholecystokinin was
dissolved in 500 jjI borate buffer at 0°C (0.18M, pH9,0, see
appendix for composition) containing 10% v/v acetone. The
solution was maintained at 0°C and a few crystals of tritiated
3sodium borohydride NaB( H) were added directly to the reaction
1 1 0  "•
mixture at approximately ten minute intervals for thirty 
minutes.
After 40 minutes the reaction mixture was applied to 
the top of a 1x15 cm column of Sephadex G15 or Bio-Gel P4, 
and the column eluted with Oo2M acetate buffer pH3,4 (see 
appendix)« 3ml fractions were collected and these were tested 
for radioactivity by mixing 5 jjl of each fraction with 10 ml 
'Aquasol* (New England Nuclear Ltd) scintillation mixture and 
counting on a scintillation counter (Phillips or Nuclear 
Enterprises)* Most of the activity was found to be contained 
in fractions 3-^5. Treatment of these fractions with 3 drops 
of glacial acetic acid had no effect on the count from these 
fractions* As any tritium present as borohydride would have 
been released as tritium gas# it was therefore concluded that 
all the tritium present in these fractions was bound to 
cho le cy s tokinlii •
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Chapter C4 Testing of Aatisera*
C4.1, Test using Cholecyatokiuin Labelled with 
C4,l$l Establishment of amount of second antibody required 
Ciiolecystokiuiu as already discussed (1.1), is a small 
molecule, and, as an antigen, is probably only mono-valent and 
as such would not precipitate spontaneously when mixed with a 
specific antibody. In order to precipitate the antibody- 
antigen (CCK) complex a second antibody directed against the 
"'globulin of the species in which the antiserum to diolecystokinin 
was raised was required.
Before any experiments ware performed it was necessary 
to determine the aiaount of this second antibody required to 
precipitate all the î(-globulin in the incubation mixture, since 
the addition of too little of the second antibody would result 
in incomplete crosslinkage, while too much of the second anti­
body would result in formation of complexes of type Ab^ Ag and 
resolubiliaation of the precipitated complex.
Dilutions of rabbit serum were prepared at strengths 
of 1 in 10, 1 in 50, 1 in 100, 1 in 400 and 1 in 800. To tubes 
containing 100 1 of these solutions were added increasing
amounts of donkey anti-rabbit precipitating serum (Wellcome 
Reagents Limited); these were 5 ^ 1  to 30 ^ 1 in 5 ^1 steps and 
thence in 10 ul steps to 200 pi.j / X , e CO 6 V V y / j
f p l i z
0 ‘8i
0  7
±: 0  4"
COc0>Q  0  3-
s
-  0 2-o.O
0 -1-
10 30 50 70 110 150 190 230 270 310
Ml Precipitating Serum Added
Fig C 4 .1  Precipltafion curve for determlnaHon of optimum amount of second 
antibody to be added to the Incubation mixture to ensure complete precipitation  
of a ll the rabbit g lobu lin .
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These solutions were mixed and incubated at 37^C for 
two hours and then at 4°C overnight* The tubes were centrifuged
in a Microfuge (Beckmann 152A) for 10 minutes * The supernatant 
was removed and the precipitate washed once with 100 vl 
distilled water. The tubes were centrifuged again and the 
supernatant removed.
The precipitate was dissolved in 400 jjl of Ü.2M sodium 
hydroxide and the optical density of the solutions at 280 nra 
determined using 500 jjl microcuvettes in an SP1800 ultraviolet 
spectrophotometer (Pye Unicam Ltd,) The results are shown in 
Pig. C4.1.
From these results it can be seen that 40 jjl of pre­
cipitating serum was necessary to ensure complete precipitation 
of all the rabbit ^-globulins* and that this was sufficient for 
all dilutions tested.
l^îï04*1.2 Testing Sera for Antibodies using ( " I) - CCK and 
" Volume Marker 
A double isotope technique based on that of Gaze, West 
& Steward (1973) was adopted as standard. All incubations 
were carried out in the 400 y/1 Microfuga Cubes (Gelman hawksley 
Limited) used as reaction vessels.
FPI13
to VACUUM 
PUMP
Fig C 4 .2  Device for removing tihe majority of the supernatant 
solution from the incubation m ixture .
Supernatant with 
22Na volume marker and freeC C K ^^I —  j -
Precipitate 
containing antibody^ bound CCK
s
— Tube as counted
Remaining — Supernatant 
— Precipitate
Fig C 4 .3  Contents of the reaction vessels before arid after 
removal o f some of the supernotont solution showing the 
final contents o f the reaction vessel which are then counted 
for radioactive con ten t.
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ïhe tubes for the assay were prepared as followsi
22 991) 5 tubes cotttaining 10 jjI " "Na as ‘ NaCl with au activity of
approximately 30^000 couuts/miuufce.
9 9  1 9 12) 5 tubes cotttainiug 10 ul m  aud 10 jjl CCK-’ I
approximately 10,000 counts/minute.
3) 3 tubes containing 10 jjI "'^ Na, 10 jjl CCK-lPl plus 100y,l
diluted serum from an unimmunised rabbit.
4) 3 tubes containing 10 yvl ^^Na, 10 ^1 GGK-^ '^ X^ plus 100
diluted test serum*
5) Repeat of (4) for all dilutions of test sera from all animals*
The tubes were capped, mixed on a vortex mixer and Incubated at 
37^C for 2 hours then overnight at 4°G* Tubes, (3), (4) and
(5) were then opened and 40 y/1 donkey anti-rabbit precipitating 
scrum added, they were then capped and incubated as before*
The tubes were centrifuged in the Microfuga for 10 minutes, 
the mg^ority of the supernatant was withdrawn by vacuum sucking 
through the device shown in fig* G4.2. This allowed quick, easy 
removal of the supernatant with just a small standard amount 
remaining in the tubes (Fig. €4.3)* The tubes were recapped 
and transferred to the /-counter (Nuclear Enterprises Limited), 
the results were printed, and the data recorded on paper tape.
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This data was then transferred to the Imperial College London 
C.DiC. 64,000 computer for processing on Its Krouos system.
The computer program is recorded in Appendix B, and examples 
of data presentation are shoxm in tables C4.X and C4;2,
3C4.2 Testing antisera using CCK-H
All the incubations were performed using 400 jjl Hicrofuge
tubes as reaction vessels4 The experiment was set up as follows :
3(A) 2 tubes containing only 10jjl GCK-U* solution,
(B) 3 tubes containing 100jjl of diluted serum from an
uniimaunised rabbit.
(G) 3 tubes containing 100jj\ of diluted test sera from each
animal,
A complete experiment of tubes A, B and C was prepared
for each dilution of the sera that was tested.
To each of the tubes in B and C was added 10 ysl CCK-H^ -
calculated to give approximately 20,000 counts per minute - the 
solutions were mixed and the tubes were then incubated at 37°G 
for 2 hourssfollowed by overnight (16 hours) at 4^C, To each
of the tubes in B and C was then added the correct amount for
that serum dilution of donkey anti-rabbit precipitating serum, 
the solutions were again mixed and incubated as before.
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Table C4.2
Presentation of results by the computer.
NA22 in 1125 Channel 1605 
NA22 26063 
SPill .0616 
Total NA22 25705
Total, 1125 CCK counts per tube 7432 
Percent Bound Tube 1 = 8.17 
Percent Bound Tube 2 = 7.89
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After Incubation the tube# were centrifuged fo# 10 
minutes in the lllcrofuge, the supernatant was removed mid the 
precipitate washed in 200 of cold Veronal Buffer Saline*
The tubes were again centrifuged foe ten minutes and the super­
natant removed#
To all tubes B and C was then added 100 ^1 'Soluene* 
(lachard Limited) and the tube# incubated at 37^C for two 
hours# At the end of 2 hours a visual check was made for 
tliû complete solution of the precipitate. The contents of 
each tube were then thoroughly mixed with 10 ml scintillation 
fluid (Aquasol, Now England Nuclear Limited) and the radio- 
activity in each tube determined on either the Phillips or 
Nuclear Enterprises Scintillation Counters*
(Phillips Liquid Scintillation Analyser PWAfOO, Nuclear 
Enterprises Automatic Sample Counter NE8312),
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Chapter C5 Processing of counter results
125 22C5.1 Results from experiments with I and ' Ha,
G5.1 a 1 Introduction
Results were obtained from the Nuclear Enterprises machines
(Automatic Sample Counter NE8311 or 8312) in the format shown, in
table C4.1. The first coluim carried the tube identification
number, the second the time to complete the count, the third
125the number of counts In the I channel, the fourth the number 
22of counts in the ’'Ha channel, while the. fifth column carried 
no relevant information. All this data was obtained simultaneously 
on punched paper tape for transfer to the computer.
€5,1,2 Transfer of data to the computer
à special file named CGKDT was created in the NULL mode 
and the data transfared to it via the teletype tape reader.
After transfer the file was listed and checked for any inaccuracies 
in the transfer,. Blank lines and errors were edited from the 
file which was then stored ready for processing.
G5»I,3 Data processing
The calculation of results was performed as in appendix C 
by the Fortran program CCE.1 (see appendix B), This was called 
from store, the computer was instructed to fetch and theniprocess 
the data contained in the file CCKBT,
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The results appeared in the format as in table G '.2, at 
no time did the amount of iodine bound by a test serum exceed 
that bound by the control serum, this would be due to either
(a) lack of a specific antibody or (b) failure to obtain a 
labelled antigen (see chapter C6)*
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Chapter C6 Problems with the radioimmunoassay
One of the main hindrances to this project has been a 
lack of material; animals have been injected with one or other 
of the two commercially available preparations of cholecystokinin 
(Boots Pancreozymin or Karolinska Cholecystokinin). Neither 
of these preparations contains more than 10% - 20% of cholecy- 
stokinin, a maximum of only 8,3^gor 26 y/g per vial respectively. 
The vials are marked in activity units, and, since it is not 
known which form of cholecystokinin (i.e. whole molecule or 
fragments) is contained in the vial, the weight of cholecy- 
stokinin contained, and the degree of antigenicity and 
immunogenicity would be considerably less if the vials contained 
only cholecystokinin fragments.
To be really sure of obtaining specific antibodies the 
animals should be injected with milligram quantities (Schlegel 
and Raptis 1976) of cholecystokinin. These however are just 
not available, and as the cost of each vial of Karolinska 
cholecystokinin was just over £11, some financial restriction 
was clearly on the project.
A limited amount of 99% pure cholecystokinin had been 
obtained as a gift from Professor Victor Mutt of the Karolinska 
Institute and it was this material, 1 yyg at a time, that was
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used to try to obtain the. radioactive antigen.
5 ? 5The process of attaching the '“‘I tracer to the cholecystokinin 
molecule was carried out according to the method described by Harvey 
et al (1974), but at the separation stage the first peak, of radio­
activity was always small, sometimes passing unnoticed. Neither 
the Chlhramine-T nor the lactoperoxidase methods seemed to work 
properly,,this despite claims to the contrary by other workers 
(Uarvey et al., 1974, Schlegel and Raptie, 1976), On occassions 
when two peaks of activity were obtained, the activity of the 
first peak, when rechromatographed only three days later, had all 
moved to the position of elution of the second, free iodide, peak 
of activity* Close examination of the atonic structure of the 
cholecys tokinin molecule revealed that with the sulphate on the 
tyrosine residue it was most likely that steric hinderance 
would prevent iodination of the tyrosine ring in the positions 
ortho to the sulphate, &md that any iodination that did occur 
would most likely be unstable.
A similar situation occurred with the attempts to label 
cholecystokinin with tritium; at the separation stage only one ' 
major peak of radioactivity could be detected. This could be 
explained only bys (a) the reaction having gone to completion or,
(b) the reaction not having occurred at all, altliougli the
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failure to eliminate free tritium with acetic acid suggests 
that the reaction did occur.
In neither case could any binding to a cholecystokinin 
antibody be demonstrated, but it is still not clear whether 
this was due to (a) a lack of antibody, (b) failure to obtain 
a labelled antigen, or (e) a combination of both. This problem 
must be resolved as it is clearly important to have both the 
radioimmunoassay and the bioassay running side by side to 
obtain the full picture of any physiological dianges that may 
occur in the system under investigation.
It seem, however, unlikely that the problems will be 
resolved until there Is a plentiful supply of pure cholecystokinin 
from either synthetic or natural sources. This will facilitate 
experiments with different labelling techniques and will ensure 
an adequate supply of cholecystokinin for cliemical modification 
to increase immunogenicity before injection to animals.
SECTION D
GENERAL DISCUSSION
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General Discussion
This project started with a working manual bioassay 
for cholecystokinin capable of producing only a maximum of 
twelve single results - six standards and six test solutions - 
each day. This assay has bead developed until it is almost 
fully automatic and capable of producing up to forty eight 
results in duplicate - a total of ninety six results - each 
day.
From being a purely research tool making slow progress, 
the technique has been developed until it forms a useful 
routine tool; large numbers of samples can be processed 
fairly quickly and a series of Investigations can now be 
completed in a relatively short space of time.
A number of anomalies in the original assay have 
been investigated and the technique modified to take these 
into account, either compensating for or eliminating them.
The first to come to light was the increase in sensitivity 
of the gall-bladder to standard solutions of cholecystokinin 
over a period of several hours. This clearly affected the 
value obtained for any unknown, the first dose-response 
curve would have a relatively shallow slope, unknowns 
processed later would thus tend to have a much greater 
cholecystokinin content attributed to them than was in 
fact the case.
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Almost simultaneously came the discovery that a 
solution of diluted serum would increase the sensitivity 
of the gall-bladder to its maximum immediately. This 
effect had been suspected during the operation of the 
manual technique, but it was not until the system was 
automated that its significance was appreciated and a 
proper trial undertaken.
As a result of these findings on the change in 
sensitivity of the gall-bladder the technique was modified 
so that the first sanples presented to each gall-bladder 
were: (1) a 5mlDU/ml dose of standard cholecystokinin 
which from experience is unlikely to be exceeded by any 
unknown, (11) and (ill) 2ml of pooled serum diluted to 
100ml. The first gave some idea of the sensitivity of 
the gall-bladder and whether or not any adjustment was 
likely to be needed in the transducer's counter balance, 
the second and third ensured that the gall-bladder was 
properly primed, that its sensitivity was maximal, before 
the samples making the calibrating dose-response curve 
were applied.
While investigating possible reasons for the high 
values obtained for serum cholecystokinin compared with
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those quoted for other gastrointestinal hormones (we had 
ng/ml instead of pg/ml) it was realised that if any 
degradation of cholecystokinin took place during processing 
and storage it was possible that a significant amount of 
cholecystokinin activity could be generated in vitro 
since some of the C-terminal fragments of cholecystokinin 
are considerably more active on a molar basis than the 
full molecule. This theory was tested by adding Trasylol 
(aprotinin, Bayer Pharmaceuticals Ltd.) to the blood 
samples. In many cases where control sasples were taken
with the experimental sample this had a dramatic effect 1
upon the apparrent cholecystokinin content of a serum j
sample and was from that time adopted as standard, all 1" Iblood samples being dispensed into 10,000 KIU Trasylol 
per lOml blood.
Finally in an experiment to compare the results 
from a radioimmunoassay with those from our bioassay it 
became apparent from the regression line that the bioassay 
was measuring something the radioimmunoassay was missing.
An experiment with dextran-coated charcoal confirmed that 
a larger, or non-peptide, substance in serum did possess 
cholecystokinin activity, Ihis activity was found to be
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constant for any individual over the period of our tests 
but to vary widely from individual to individual. It is 
now standard practice to measure this 'serum blank' and 
to subtract its value from the total cholecystokinin activity 
of that sample.
This work has confirmed that cholecystokinin acts 
directly on the gall-bladder tissue, and shown that the 
effects of other gastrointestinal hormones are not sufficiently 
significant to affect the assay thus despite some interference 
by the hormones it may still be said with confidence that 
the system is specific for cholecystokinin.
With the discovery of a 'big cholecystokinin' by 
chromatographic means we must speculate as to whether or 
not it is this big molecule that forms the activity we 
have termed the 'serum blank'. This seems the most likely 
explanation despite the fact that digestion with trypsin 
did not release small, more active, fragments. The release 
of these fragn^nts would in fact o%ly take place if the 
nature of the large molecule was such that the C-terminal 
end of the cholecystokinin was free and exposed; under 
other circumstances, although the trypsin might split the 
molecule an increase in activity would not necessarily 
take place.
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The idea of a *big cholecystokinin' falls nicely into 
place beside 'big* and 'big, big* gastrins (Rehfeld et al. 
1974), and although firmly established as existing, the 
structure and functions of these molecules, apart from 
'big* (G34) gastrin, are not yet known. It is possible 
that 'big* cholecystokinin is a precursor form being attached 
perhaps to a glycoprotein in a manner similar to ACTU 
(Eipper, Mains and Guenai, 1976)$ It's apparent reduction 
during the period following a meal would support the 
precursor idea, but whether it is a peptidoglycan or a 
simple polymer is not yet known and requires further 
investigation,
* or another peptide in a manner similar to proinsulin 
(Steiner, Clark, Nolan, Rubenstein, Margoliash, Aten and 
Oyer, 1969).
The theoretical simplicity of setting up a radio- 
insaunoassay for a given substance is well documented; 
inject an animal with the substance, harvest the antibody 
containing serum, attach a radioactive tracer atom to the 
pure substance and react with the antibody containing 
serum. This simple theory has not worked at all with 
cholecystokinin; one of the major problems is isolating
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\diich of the above steps has failed# It would indeed 
appear very like a 'chicken or the egg* situation: to
test for an antibody we must have a labelled antigen, but 
at the same time, to be sure that we have a labelled 
antigen we must possess a specific antibody to the antigen# 
We are not unique in finding problems with a 
radioimmunoassay for cholecystokinin as similar problems 
have already been reported (Rehfeld, 1978), and it must 
be expected that until adequate supplies of cholecystokinin 
at a reasonable price become available, these difficulties 
will remain with us#
The results from the clinical investigations, while 
inconclusive in several cases, have nevertheless been 
extremely interesting! Tims clear evidence has been obtained 
that fasting serum levels of cholecystokinin rise following 
a cholecystectomy operation. The reason for thia is not 
known although Caroll, Lemonnier, Charpentier and Flossier 
(1963) have suggested that a cholecystokinin inhibitor is 
manufactured in and released from the mucosa of the neck 
of the gall-bladder# There is little supporting evidence 
for this theory which would however provide a very simple 
©2îplanation for our findings; the renKJval of the source of
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an inhibitor would naturally load to an increase in the |Iactivity of the original molecule. iJ
However it could also be said that with the removal !■ 'I
of a target organ the body is trying hard to produce the !
■ - isame effect ** perhaps by stimulating bile flow (something |
cholecystokinin is not believed to do efficiently) - and I
achieve an efficient emulaification of fat within tlie 1
■ 4
duodenum, With the loss of the storage organ, increased I
i
normal flow would be the natural way to maintain normal !:|
conditions. j
Til at the opposite should occur when a highly selective j
. ivagotomy operation is performed is not at all surprising, }• 'I
This operation is usually performed to correct an ulcerative i
condition, and ulcers have often been caused by irritation
■ ■ Jand erosion of the gut mucosa by an excess of acid. Acid j
has already (chapter A4,2) been shown to be an excellent j
stimulator of cholecystokinin release, thus a person 
producing an excess of stomach acid would be continuously
passing thia to the duodenum and stimulating cholecystokinin j
release. j
' jSevering the vagus nerve at specific points cuts I
off the impetus for gastrin release and, as a direct result 1
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the amount of stomach acid released is reduced. This 
reduces the irritation to the gut mucosa and allows the 
ulcer to heal; at the same time the continuous stimulus 
for cholecystokinin release is cut off and fasting levels 
of serum cholecystokinin drop.
In other clinical conditions we have seen how the 
response to a meal is slow and small following Roux - en - 
Y operations, but the trend in other gastric operations io 
as yet unclear. It has been shown in the case of hyper- 
phagic obese patients that their abnormal appetites are 
not due to failure of cholecystokinin release, but must, 
if cholecystokinin is to be implicated at all, be due to 
a failure at the receptor sites.
Tliere is also some evidence (Monk, Johnson and 
Marshall, unpublished results) that the level of serum 
cholecystokinin can be correlated with the diaiaeter of 
the pyloric sphincter. It was often found that patients 
with low fasting levels of cholecystokinin had relaxed 
and open pyloric sphincters through whidi investigative 
tubes could be pushed with ease. In patients with high 
fasting levels of serum cholecystokinin the pyloric 
sphincter was frequently shut and contracted so tightly 
that it would not permit the passage of investigative 
tubes.
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This thesis has therefore presented two methods of 
estimating cholecystokinin in human serum and has examined 
the problems involved in both methods. Some of the problems 
have been solved, others remain to be solved so that the 
two assays can be set to work in parallel.
Some clinically interesting conditions have been 
examined and several indications have been obtained. It 
is clear from the diverse reports found in the current 
literature that far from being completely, documented 
the cholecystokinin story is probably only just beginning, 
unlike other gastric hormones, e.g. gastrin, cholecystokinin 
has only been characterised in one species. It will be 
most interesting to see how much sequence variation occurs 
in other species.
A few years ago cholecystokinin was credited with 
only two target organs - the gall-bladder and the pancreas - 
more recently it has been associated with pyloric control, 
gut - in particular colonic - motility, and has also been 
implicated as a sateity signal. Its commercial availability 
has led to its use in cholecystogram studies.
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A lot is still to be discovered about this hormone, 
its functions and relationship with the other gastrointestinal 
hormones, It is probable that diole cys tokinin will be 
found to influence several more body organs before the 
full story is knoim* In the laeantima one of the first 
priorities must be to establish the tools with which to 
carry out the investigations, and thia means the establish­
ment of a reliable and highly specific radioimmunoassay to 
work alongside the automated bioassay described in this thesis.
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APPENDIX A - BUFFER SOLUTIONS
1). Krebs Balanced Salts Solution pH 7.4
MgSO^.IH^O. 0.29g
Glucose l.OOg
NaCL 6.90g.
KCL 0.35g
KH^PO^ 0.16g
NaHCOg 2.10g
CaCL 6H2O 0.55g
The above quantities were dissolved in distilled water to 1 litre.
2). Sorensen’s Phosphate Buffer 0.05M, pH 7.4
Stock Solutions: A; 1/15M KH^PO = 9.08g KH^PO^/litre
B; 1/15M Na HPO^= 9.48g Na^HPO /litre 
for pH 7.4 buffer add 19.6 ml A to 80.4 ml B
3). Veronal Buffered Saline (V.B.S.)
Stock Solutions: A; Sodium Barbitone 20,62g/litre
B; 0.IN Hydrochloric Acid 
C; O.OIM Sodium Chloride 
for buffer pH 7.6 add 60 ml A to 30 ml B and make to 
1 litre with C
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4). Borate buffer 0.2M pH9.0
Stock Solutions: A; 0.4M Boric Acid in 0.4M KCl.
(24.8g HgBO + 39.84 KCl per litre)
B; O.IN Sodium Hydroxide 
for buffer pH 9.0 add tO ml A to 21.3 ml B and dilute 
to 100 ml.
5). Acetate Buffer 0.2M pH3.6
Stock solutions A; 0.4M Acetic Acid (24g/litre)
B; 0.4M Sodium Acetate (16.4g/litre
CH^ COONa, 27.2g/litre CH^ COONa. BH^O 
For buffer pH 3.6 add 46.3 ml A to 3.7 ml B and dilute 
to 100 ml.
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APPENDIX B - COMPUTER PROGRAM 
200 PROGRAM CCKl (INPUT, OUTPUT, CCKDT, TAPE5=INPUT, TAPE6= 
OUTPUT, TAPE 7=CCDT)
250 DIMENSION ATOTS (5), SODS (4)
300 1 FORMAT (5X,*NUMBER OF SETS OF DATA THIS RUN*)
350 2 FORMAT (12)
400 3 FORMAT (IX, 12, 1X,F8.2,F7.0,F7.0)
450 4 FORMAT (5X,*NA22 IN 1125 CHANNEL *, F7.0)
500 5 FORMAT (5X,*NA22,F7.0)
550 6 FORMAT(5X,*SPILL*,F6.4)
600 7 FORMAT(5,*TOTAL NA22*,F7.0)
650 8 FORMAT(5X,*TOTAL 1125 CCK COUNTS PER TUBE*,F7.0)
700 9 FORMAT(5X,*PERCENT BOUND TUBE*,13,*=*,F6.2)
750 WRITE(6.1)
800 READ(5.2)INOM
850 IF(IN0M.GT.90)G0T0.600
900 READ(7.3)IL(ATOTS(l),1=1,3)
950 DO 500 I=1,IN0M 
1000 IT=0 
1050 DO 100 J=l,4 
1100 100 SODS(J)=0.0 
1150 DO 200 J=l,5 
1200 IF(IL.GT.5)G0T0 250
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1250 AT0TS(2)=AT0TS(2)/AT0TS(1)
1300 S0DS(1)=S0DS(1)+AT0TS(2)
1350 AT0TS(3)=AT0TS(3)/AT0TS(1)
1400 SODS(2)=SODS(2)+ATOTS(3)
1450IT=IT+1
1500 READ(7.3)IL,(ATOTS(K),K=I.3)
1550 200 CONTINUE
1600 250 S0DS(1)=60/IT*S0DS(1)
1650 S0DS(2)=60/IT*S0DS(2)
1700 WRITE(6.4)SODS(1)
1750 WRITE(6.5)SODS(2)
1800 SPILL=S0DS(1)/S0DS(2)
1850 WRITE(6.6)SPILL
1900 IT=0
1950 DO 300 J=l,5
2000 IF(IL.GT.10)G0T0 350
2050 ATOTS(3)=AT0TS(3)/ATOTS(1)*60
2100 SODS(3)=SODS(3)+ATOTS(3)
2150 ATOTS(2)=AT0TS(2)/ATOTS(1)*60-SPILL*AT0TS(3) 
2200 S0DS(4)=S0DS(4)+AT0TS(2)
2250IT=IT+1
2300 READ(7,3)IL,(AT0TS(K),K=1,3)
2350 300 CONTINUE
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2400 350 S0DS(3)=S0DS(3)/IT 
2450 SODS(4)=SODS(4)/IT 
2500 WRITE(6,7)SODS(3)
2550 WRITE(6,8)SODS(4)
2600 400 AT0TS(3)=AT0TS(3)/AT0TS(1)*60 
2650 ATOTS(2)=ATOTS(2)/ATOTS(1)*60-SPILL*AT0TS(3) 
2700 ATOTS(2)=ATOTS(2)*SODS(3)-SODS(4)*ATOTS(3) 
2750 ATOTS(3)=SODS(4)*(SODS(3)-ATOTS(3))
2800 ATOTS(2)=ATOTS(2)/ATOTS(3)*100
2825 IL=IL-10
2850 WRITE(6,9)IL,ATOTS(2)
2900 READ(7,3)IL,(ATOTS(J),J=1,3)
2950 IF(IL.LE.10)GOTO 500
3000 GOTO 400
3050 500 CONTINUE
3100 600 STOP
3150 END
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APPENDIX C - CALCULATIONS
22 1251. Double Isotope technique using Na and I
With two isotopes the possibility of a spill of counts
from one channel to the other must be examined. At the levels
125 . 125 . 22 of I used the spill of I counts into the Na channel
was around 0.3% and not considered significant. The spill
22 125from the Na channel to the I channel was however of the
order of 5% and was corrected as follows (based on Gaze, West
and Steward, 1973).
125Total I counts added per tube corrected for spill;
1=1'-m 
y 125where I’ = Total counts in I channel including spill
22N = Total count in Na channel 
125X = Counts in I channel in tubes containing
22 ,^ ,Na only
22Y = Counts in Na channel in tubes containing
22Na only
125counts in I channel of experimental tubes corrected 
for spill 1=1’-Nx
y
125Wliere I ’ = counts in I channel of experimental tube 
including spill
22N = counts in Na channel of experimental tube.
then% antigen bound = (NI - NI) ,
I(N - n) *  ^°
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APPENDIX E
Defihition o£ Normal, Obese and Hyperphagic Patients
1. A normal patient was a normal weight subject with a weight 
around the ideal i.e. from 20% below ideal weight to 19%
above ideal. Ideal body weight was defined as that corresponding 
to the mid-point of the weight range for medium frame sise as
listed in the weight for height tables of the Metropolitan
. • ■ 1Life Insurance Company .
2. Obese subjects are those with a weight 20% or more above ideal 
weight *
3. Intake of food was assessed by dietary recall with weighing
of food once per week, A normal appetite, was based in the
recommended figures for intake as listed in the Government
2figuresÎ FAO Standards , Abnormal intake was a.two-fold or 
greater intake than the standard figure for age, se::, occupation 
and height.
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